
<rss version="0.91">
    <channel>
        <title>Latest Articles from Folia Medica</title>
        <description>Latest 100 Articles from Folia Medica</description>
        <link>https://foliamedica.bg/</link>
        <lastBuildDate>Mon, 9 Nov 2026 21:19:10 +0000</lastBuildDate>
        <generator>Pensoft FeedCreator</generator>
        <image>
            <url>https://foliamedica.bg/i/logo.jpg</url>
            <title>Latest Articles from Folia Medica</title>
            <link>https://foliamedica.bg/</link>
            <description><![CDATA[Feed provided by https://foliamedica.bg/. Click to visit.]]></description>
        </image>
	
		<item>
		    <title>Exosomal microRNA signatures in the crossroads of periodontitis and HNSCC</title>
		    <link>https://foliamedica.bg/article/181146/</link>
		    <description><![CDATA[
					<p>Folia Medica 68(5): e181146</p>
					<p>DOI: 10.3897/folmed.68.e181146</p>
					<p>Authors: Anitha Pandi, Vijayashree Priyadharsini J</p>
					<p>Abstract: Introduction: Inflammatory pathways are considered the crossroads of oral cancer and periodontitis. Exosomal microRNAs (miRNAs) have emerged as key regulators linking inflammation and carcinogenesis.         Aim: This study aimed to identify differentially expressed miRNAs associated with periodontitis (PD) and evaluate their relevance in head and neck squamous cell carcinoma (HNSCC) using a bioinformatics approach.         Materials and methods: miRNA expression data from the GSE89081 dataset (n=10) were analyzed using GEO2R with an adjusted p-value of &lt;0.05. Selected miRNAs were validated in the TCGA-HNSCC dataset via UALCAN, followed by survival analysis. Exosomal localization and target gene prediction were performed using ExoCarta and TargetScan.         Results: Among the 25 microRNAs curated from the dataset based on statistical significance, five were significantly expressed in HNSCC and had a notable impact on patient survival. A set of differentially expressed miRNAs was identified, among which hsa-miR-193b-5p and hsa-miR-877-5p were consistently upregulated in both PD and HNSCC datasets. Higher expression levels of these miRNAs were associated with reduced overall survival.         Conclusions: The microRNAs, hsa-miR-193b-5p, and hsa-miR-877-5p were significantly upregulated in both datasets. Also, overexpression of these microRNAs was associated with reduced overall survival in patients with HNSCC. Furthermore, low expression of the target transcript of hsa-miR-193b-5p, FLI1, was associated with poor survival in HNSCC patients. These findings suggest a potential role in inflammation-associated carcinogenesis; however, due to the small sample size and in silico design, further experimental validation is warranted.</p>
					<p><a href="https://foliamedica.bg/article/181146/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/181146/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/181146/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Fri, 30 Oct 2026 07:00:03 +0000</pubDate>
		</item>
	
		<item>
		    <title>Early peripheral T-cell immune dynamics during anti-PD-1 therapy as potential biomarkers of treatment response in metastatic non-small cell lung cancer: a prospective pilot study</title>
		    <link>https://foliamedica.bg/article/188485/</link>
		    <description><![CDATA[
					<p>Folia Medica 68(5): e188485</p>
					<p>DOI: 10.3897/folmed.68.e188485</p>
					<p>Authors: Antoan Garev, Nevena Gesheva, Elisaveta Naumova, Katerina Mishovska, Nikolay Garev, Zhasmina Mihaylova</p>
					<p>Abstract: Introduction: Reliable peripheral immune biomarkers for monitoring response to anti-PD-1 therapy in metastatic NSCLC remain poorly defined. Dynamic changes within circulating T-cell compartments may reflect early pharmacodynamic immune remodeling associated with treatment response.         Aim: To evaluate early peripheral T-cell immune dynamics during anti-PD-1 therapy and explore their potential as biomarkers of radiologic response.         Materials and methods: Prospective paired peripheral blood immune profiling was performed in patients with metastatic NSCLC treated with pembrolizumab-based combination immunochemotherapy at baseline and after completion of four treatment cycles. Multicolor flow cytometry was used to assess T-cell activation (CD69), co-stimulatory competence (CD8⁺ CD28⁺), and regulatory T cells (Treg). Baseline-to-cycle-4 changes were analyzed descriptively and compared according to radiologic response.         Results: Four patients with paired immune assessments were included. Two achieved partial response (PR) and two had stable disease (SD). Early peripheral immune remodeling was observed across patients, characterized by decreased CD4⁺ CD69⁺ and CD8⁺ CD69⁺ T cells and increased Treg frequencies. A consistent increase in CD8⁺ CD28⁺ T cells was observed in PR patients, whereas SD patients demonstrated heterogeneous changes. These findings suggest differential early modulation of CD8⁺ co-stimulatory capacity according to treatment response.         Conclusions: Early peripheral T-cell immune dynamics during pembrolizumab-based immunochemotherapy may reflect biologically relevant immune remodeling associated with radiologic response. Serial flow-cytometric monitoring of CD8⁺ CD28⁺ T cells may represent a promising candidate peripheral biomarker and warrants further investigation in larger cohorts.</p>
					<p><a href="https://foliamedica.bg/article/188485/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/188485/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/188485/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Thu, 22 Oct 2026 18:06:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>A case of rare metanephric neoplasm resembling renal cell carcinoma: metanephric stromal tumor</title>
		    <link>https://foliamedica.bg/article/165007/</link>
		    <description><![CDATA[
					<p>Folia Medica 68(5): e165007</p>
					<p>DOI: 10.3897/folmed.67.e165007</p>
					<p>Authors: Cagri Sevik, Akif Erbin, Onuralp Nisli, Osman Can, Ruveyda Erarslan Selcuk, Alper Kocbiyik, Halil Lütfi Canat</p>
					<p>Abstract: Metanephric neoplasms (MNs) represent an uncommon subset of benign renal tumors, encompassing entities such as metanephric adenoma, metanephric stromal tumor (MST), and metanephric adenofibroma. Despite the limitations of radiological modalities in accurately differentiating these lesions, their characteristic histopathological architecture and unique immunohistochemical markers are crucial for establishing a definitive diagnosis and distinguishing them from other renal malignancies. In this case report, we describe the diagnostic and treatment process for a 25-year-old woman who was incidentally diagnosed with an MST after undergoing a radical nephrectomy, backed by an analysis of recent research.</p>
					<p><a href="https://foliamedica.bg/article/165007/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/165007/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/165007/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Thu, 22 Oct 2026 18:06:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia: a case series</title>
		    <link>https://foliamedica.bg/article/160141/</link>
		    <description><![CDATA[
					<p>Folia Medica 68(5): e160141</p>
					<p>DOI: 10.3897/folmed.68.e160141</p>
					<p>Authors: Paschalis Evangelidis, Konstantinos Tragiannidis, Vassiliki Antari, Aliki Ioakimidou, Eleni Gavriilaki, Vassiliki Tsavdaridou, Lemonia Skoura, Assimina Galli-Tsinopoulou, Emmanuel Hatzipantelis, Athanasios Tragiannidis</p>
					<p>Abstract: The introduction and usage of novel therapies and monoclonal antibodies in pediatric acute lymphoblastic leukemia (ALL) resulted in the achievement of higher survival rates in these patients. Recently, inotuzumab ozogamicin (InO), a CD22 antibody, received approval for pediatric ALL, and the first results published from studies worldwide are encouraging, especially in patients with relapsed or refractory (r/r) disease. In our study, the case series presented consists of three pediatric patients with ALL that relapsed after the first treatment of the disease. The three children with r/r acute lymphoblastic leukemia underwent treatment with InO. All of them, after 1 or 2 immunotherapy cycles with InO, achieved negative MRD and did not present any treatment-related toxicities. In our retrospective study, InO was shown to be a safe and effective treatment for r/r B-ALL in pediatric patients.</p>
					<p><a href="https://foliamedica.bg/article/160141/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/160141/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/160141/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Thu, 22 Oct 2026 14:51:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Assessment of NGAL, eGFR, and tubular injury markers for early detection of chemotherapy-induced nephrotoxicity in pediatric oncology patients</title>
		    <link>https://foliamedica.bg/article/184913/</link>
		    <description><![CDATA[
					<p>Folia Medica 68(4): e184913</p>
					<p>DOI: 10.3897/folmed.68.e184913</p>
					<p>Authors: Petya Markova, Antoniya Yaneva, Mariya Spasova, Stoyan Markov, Kostadin Kostadinov</p>
					<p>Abstract: Introduction: Acute kidney injury is a common complication in children with oncological diseases. Its etiology is multifactorial, with key risk factors including drug-induced nephrotoxicity, tumor lysis syndrome, and infection—including sepsis during periods of aplasia. The classical diagnostic criteria for AKI rely on monitoring serum creatinine levels and detecting oliguria. In the context of drug-induced nephrotoxicity, the predominant pathophysiological mechanism is tubular injury, which is typically non-oliguric and may not cause changes in serum creatinine, even in cases of severe damage.         Materials and methods: We studied 40 children undergoing 116 chemotherapy cycles with nephrotoxic agents at the Pediatric Hematology-Oncology Department, St. George University Hospital. Urinary NGAL, estimated GFR (eGFR) using the Schwartz, Schwartz-adjusted, and Brandt formulas, and tubular markers—fractional excretion of phosphate (FeP) and tubular maximum reabsorption of phosphate per GFR (Tmp/GFR)—were measured before and 12 hours after each cycle.         Results: Urinary NGAL increased significantly after later chemotherapy cycles but remained within reference ranges and failed to detect two KDIGO-defined AKI episodes. The classical Schwartz formula identified only two AKI cases, while adjusted formulas revealed decreased eGFR in 36% of patients and a reduction in hyperfiltration prevalence from 50% to 28%. Tubular markers (FeP, Tmp/GFR) showed consistent and significant changes across all cycles.         Conclusion: NGAL is not a reliable early biomarker for chemotherapy-related AKI in children. Adjusted eGFR formulas and tubular injury markers provide greater sensitivity and should be incorporated into monitoring protocols to enable earlier detection and reduce the risk of chronic kidney damage.</p>
					<p><a href="https://foliamedica.bg/article/184913/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/184913/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/184913/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Mon, 31 Aug 2026 09:47:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>The association of hypoxia-inducible factor-1 alpha expression, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio with three-year progression-free survival in locally advanced colorectal cancer patients</title>
		    <link>https://foliamedica.bg/article/180500/</link>
		    <description><![CDATA[
					<p>Folia Medica 68(4): e180500</p>
					<p>DOI: 10.3897/folmed.68.e180500</p>
					<p>Authors: Galuh Chandra Kirana Sugianto, Rahmat Cahyanur, Nur Rahadiani, Cleopas Martin Rumende</p>
					<p>Abstract: Abstract         Introduction: Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide and ranks among the top three in Indonesia. Most patients were diagnosed in a locally advanced stage, with a high recurrence rate despite standard oxaliplatin-based chemotherapy. The hypoxic tumor microenvironment through activation of HIF-1α and systemic inflammation reflected by the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) could be associated with the tumor progression.         Aim: To evaluate the association of HIF-1α expression, NLR, and PLR with three-year progression-free survival (PFS) in locally advanced CRC patients.         Methods: This retrospective cohort study included 50 patients with high-risk stage II and stage III CRC who underwent surgical resection and adjuvant oxaliplatin-based chemotherapy in Cipto Mangunkusumo National Hospital. HIF-1α expression was assessed by immunohistochemistry, while NLR and PLR were calculated from pre-treatment blood tests. Data were analyzed using Kaplan–Meier and Cox regression methods, with p&lt;0.05 considered statistically significant.         Results: The median HIF-1α expression was 96.32%, with a cut-off value of 96.51% (AUC 0.472; p=0.746). There was no significant association between HIF-1α expression and three-year PFS (HR 1.274; p=0.495). The cut-off points for NLR and PLR were 3.46 (AUC 0.486; p=0.872) and 198.31 (AUC 0.505; p=0.952), respectively, and both were not significantly associated with three-year PFS (NLR: HR 0.947; p=0.874; PLR: HR 1.060; p=0.869).         Conclusions: HIF-1α expression, NLR, and PLR were not significantly associated with three-year progression-free survival in locally advanced CRC patients.</p>
					<p><a href="https://foliamedica.bg/article/180500/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/180500/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/180500/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Thu, 13 Aug 2026 15:18:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Impact of PD-1 inhibitor immunotherapy on survival in patients with newly diagnosed and recurrent glioblastoma: a systematic review of comparative evidence</title>
		    <link>https://foliamedica.bg/article/184377/</link>
		    <description><![CDATA[
					<p>Folia Medica 68(4): e184377</p>
					<p>DOI: 10.3897/folmed.68.e184377</p>
					<p>Authors: Renindra Ananda Aman, Theresia Meiske Laura Siscawati Wayne, Fadli Hamdilah, Muhammad Wasistha Adriantama</p>
					<p>Abstract: Abstract         Introduction: Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor. PD-1 inhibitors have shown potential use in GBM. There is some evidence to suggest that programmed death-1 (PD-1) inhibitors may be effective in treating GBM. However, the results of clinical trials conducted to date have been inconclusive, which has led to questions regarding the efficacy of PD-1 inhibitors in this context.         Aim: This systematic review aimed to evaluate whether PD-1 inhibitors provide a survival advantage over the standard regimens in GBM.         Materials and methods: This review followed the PRISMA guidelines. Comprehensive searches were conducted in PubMed, Scopus, and the Cochrane Library from 2015 to 2025. The extracted data included the study design, sample characteristics, interventions, comparators, and reported survival outcomes. The risk of bias was assessed using the Cochrane RoB 2 tool.         Results: Four trials were included in this review. In newly diagnosed GBM, PD-1 inhibitors plus radiotherapy showed an inferior overall survival (OS) rate compared to standard regimens (median OS [mOS] 13.4 vs. 14.9 months, HR 1.31 [95% CI: 1.09-1.58]). PD-1 inhibitors as an adjuvant to temozolomide-based therapy also showed no statistically significant improvement in OS (mOS 11.6 vs. 11.8 months, HR 0.85 [95% CI 0.54-1.33]) or progression-free survival (PFS) (median PFS [mPFS] 7.4 vs. 5.9 months, HR 0.77 [95% CI 0.49- 1.19]) compared to placebo. For recurrent GBM, there was no significant difference in OS between nivolumab and bevacizumab (mOS 11.6 vs. 10.0 months, HR 1.04 [95% CI: 0.83-1.3]). Consistently, PD-1 inhibitors did not demonstrate a survival advantage in either newly diagnosed or recurrent glioblastoma.         Conclusion: PD-1 inhibitors showed no statistically significant improvement in OS and PFS in patients with GBM.</p>
					<p><a href="https://foliamedica.bg/article/184377/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/184377/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/184377/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Thu, 13 Aug 2026 10:48:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>A gastric metastasis from ovarian carcinoma mimicking GIST – a case report</title>
		    <link>https://foliamedica.bg/article/153213/</link>
		    <description><![CDATA[
					<p>Folia Medica 68(4): e153213</p>
					<p>DOI: 10.3897/folmed.68.e153213</p>
					<p>Authors: Teodor Sofiyanski, Elena Popova, Sonya Sergieva, Bozhil Robev, Boryana Ilcheva, Albena Fakirova</p>
					<p>Abstract: Abstract         Ovarian cancer has the highest mortality rate among gynecological malignancies. Metastatic sites are most commonly found in the peritoneum, pelvic organs, and lymph nodes, followed by the liver, distant lymph nodes, lungs, bones, and brain. There have only been a few reports of distant metastases in the stomach.         Herein, we present a rare case of a 59-year-old woman with high-grade serous ovarian carcinoma with a single metastasis in the stomach. The post-surgery follow-up was performed with 18F-FDG PET/CT. The patient remained recurrence-free for 3 years. On a routine follow-up PET/CT scan, an intramural hypermetabolic lesion in the stomach, suggestive of GIST, was detected. A biopsy confirmed a metastasis from high-grade serous ovarian carcinoma. A “Reverse Krukenberg” tumor—a gastric metastasis from ovarian cancer—is extremely uncommon. The exact mechanism of spreading to the stomach is still unknown. Even though gastric metastasis from ovarian carcinoma is uncommon, we advise clinicians to stay mindful of the potential for gastric metastasis in patients with a history of ovarian cancer.</p>
					<p><a href="https://foliamedica.bg/article/153213/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/153213/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/153213/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Thu, 6 Aug 2026 15:01:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Immunoscore as a prognostic marker in colorectal cancer</title>
		    <link>https://foliamedica.bg/article/163476/</link>
		    <description><![CDATA[
					<p>Folia Medica 68(4): e163476</p>
					<p>DOI: 10.3897/folmed.68.e163476</p>
					<p>Authors: Yanislav Grishev Iliev, Vladimir Nikolov Andonov, Elena Galabova Poryazova-Markova</p>
					<p>Abstract: Abstract         Introduction: Colorectal cancer is a leading cause of morbidity and mortality worldwide. Immunoscore provides important prognostic information in early-stage colorectal cancer, beyond traditional TNM staging.         Aim: To investigate the Immunoscore in early-stage colorectal cancer and its prognostic value.         Patients and methods: A retrospective pilot cohort of 35 patients was evaluated for recurrence, survival, toxicity, and clinical correlations with Immunoscore.         Results: High Immunoscore was associated with better outcomes, including zero recurrence. Immunoscore showed trends by tumor location, with stronger associations in younger patients. There was no correlation with carcinoembryonic antigen levels.         Conclusion: Our findings support the incorporation of Immunoscore into future colorectal cancer staging models.</p>
					<p><a href="https://foliamedica.bg/article/163476/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/163476/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/163476/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Thu, 6 Aug 2026 11:17:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Gastric DLBCL presenting as multiple gastric ulcers: a case report</title>
		    <link>https://foliamedica.bg/article/155005/</link>
		    <description><![CDATA[
					<p>Folia Medica 68(3): e155005</p>
					<p>DOI: 10.3897/folmed.68.e155005</p>
					<p>Authors: Wulyo Rajabto, Lugyanti Sukrisman, Agnes Stephanie Harahap, Maria Pyrhadistya, Ainun Safitri</p>
					<p>Abstract: Gastric diffuse large B-cell lymphoma (DLBCL) comprises most of all gastrointestinal lymphomas, accounting for approximately 55%–65% of all cases. This condition predominantly affects male patients and those older than 50 years and is usually aggressive. The clinical presentations are nonspecific and can mimic other diseases. In this report, we present a case of a 66-year-old male patient with a history of hematemesis and melena, with significant weight loss for 3 months. Esophagogastroduodenoscopy (EGD) revealed multiple stomach ulcers. A biopsy taken during EGD, which was followed by immunohistochemical staining, confirmed the diagnosis of non-Hodgkin lymphoma, specifically germinal center B-cell (GCB)–subtype DLBCL. A positron emission tomography (PET) scan was performed, revealing the involvement of the mesenteric lymph nodes and an infiltrative lesion that extended from the stomach to the pancreas. Based on the Ann Arbor staging system, the diagnosis was identified to be stage IV gastric DLBCL. Following diagnosis, we administered rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (R-CHOP) to the patient.</p>
					<p><a href="https://foliamedica.bg/article/155005/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/155005/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/155005/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Tue, 30 Jun 2026 17:21:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Risk factors for visceral metastases in cutaneous melanoma: insights from a clinical cohort</title>
		    <link>https://foliamedica.bg/article/167983/</link>
		    <description><![CDATA[
					<p>Folia Medica 68(2): e167983</p>
					<p>DOI: 10.3897/folmed.68.e167983</p>
					<p>Authors: Luiz-Sorin Vasiu, Razvan Danciu, Laura Raducu, Cristian Radu Jecan</p>
					<p>Abstract: Introduction: Cutaneous melanoma, a malignancy originating from melanocytes, is characterized by a high propensity for metastatic spread. It commonly affects the lungs, liver, brain, lymph nodes, and skin.         Aim: This study examines a cohort of cutaneous melanoma patients diagnosed with metastatic disease at our institution, aiming to identify patterns and risk factors associated with metastatic spread.         Materials and methods: A retrospective analysis was conducted on 49 patients treated for cutaneous melanoma in our plastic surgery ward between 2017 and 2022 who subsequently developed metastatic disease.         Results: Over six years, 49 of 130 melanoma cases progressed to metastases. T4 lesions predominated (55.1%). Metastases involved multiple organs in 42.9% of cases. Males had more advanced disease compared to women, with a higher mean Breslow Index, higher ulceration rates, greater metastatic burden.         Despite being a visible tumor, cutaneous melanoma can remain undetected until advanced stages, emphasizing the need for public awareness and early screening. Our study confirms that even thin melanomas (&lt;1 mm) can metastasize, particularly to the lungs, challenging the assumption that low Breslow index ensures favorable prognosis. The high incidence of multiorgan involvement, especially in male and nodular melanoma patients, highlights the aggressive nature of certain subtypes and the importance of personalized follow-up strategies.         Conclusions: Male patients demonstrated more aggressive disease patterns, highlighting the need for early detection and tailored management. Subtype-specific metastatic patterns warrant further investigation to improve prognostic and therapeutic strategies.</p>
					<p><a href="https://foliamedica.bg/article/167983/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/167983/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/167983/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Fri, 3 Apr 2026 18:00:13 +0000</pubDate>
		</item>
	
		<item>
		    <title>Clinical case of a patient with fatal development of gas gangrene while using totally implantable venous access devices</title>
		    <link>https://foliamedica.bg/article/146721/</link>
		    <description><![CDATA[
					<p>Folia Medica 68(1): e146721</p>
					<p>DOI: 10.3897/folmed.68.e146721</p>
					<p>Authors: Buryan Kirov, Plamen Murdzhanov, Angel Petkov</p>
					<p>Abstract: Gas gangrene, or clostridial myonecrosis, is a rare and life-threatening infection caused primarily by Clostridium perfringens. Despite its reduced incidence due to advancements in wound care and antibiotics, the disease remains associated with significant morbidity and mortality, particularly in immunocompromised individuals. This report presents a clinical case of a 37-year-old male with esophageal carcinoma and a totally implantable venous access device (Port-a-Cath), who developed fatal gas gangrene following chemotherapy.         The patient presented with rapidly progressing symptoms, including fever, extensive edema, crepitus, and necrotic bullous lesions of the right upper limb and thoracic region. Despite prompt multidisciplinary evaluations and surgical intervention, the patient succumbed to infectious shock and cardiac arrest shortly after the initial incision. This case underscores the critical need for early clinical recognition of gas gangrene, especially by surgeons and emergency physicians, to initiate life-saving surgical debridement and adjunctive therapies.         This report also highlights the interplay of modern medical devices with rare but catastrophic infections, emphasizing the necessity of vigilant monitoring and robust infection control protocols in high-risk patients. Through this unique presentation, we aim to enhance awareness and diagnostic acumen among healthcare professionals, advocating for interdisciplinary approaches and evidence-based guidelines to mitigate the devastating impact of gas gangrene in similar clinical contexts.</p>
					<p><a href="https://foliamedica.bg/article/146721/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/146721/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/146721/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Thu, 26 Feb 2026 00:07:33 +0000</pubDate>
		</item>
	
		<item>
		    <title>Papillary fibroelastoma in an unusual location: arising from the left atrial endocardium</title>
		    <link>https://foliamedica.bg/article/145258/</link>
		    <description><![CDATA[
					<p>Folia Medica 67(6): e145258</p>
					<p>DOI: 10.3897/folmed.67.e145258</p>
					<p>Authors: Assen S. Keltchev, Kristiyanna M. Mavrodieva</p>
					<p>Abstract: Abstract     Papillary fibroelastoma (PFE) is a rare, benign cardiac tumor, often asymptomatic and typically arising from the valvular endocardium. While predominantly located on the heart valves, involvement of the atrial chamber is exceptionally uncommon. This case report presents a 34-year-old female with a history of ischemic stroke, in whom a left atrial mass was subsequently identified. Notably, the tumor was attached to the left atrial endocardium near the left atrial appendage orifice and the anterior mitral leaflet, an unusual location for PFE that made diagnosis difficult. Initially suspected to be a myxoma, the lesion was definitively diagnosed as a papillary fibroelastoma following histopathological examination. This case underscores the importance of advanced imaging techniques, meticulous preoperative evaluation, and histological confirmation in diagnosing and managing cardiac tumors in unusual locations.</p>
					<p><a href="https://foliamedica.bg/article/145258/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/145258/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/145258/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Thu, 18 Dec 2025 20:22:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Metastatic primary bifocal germinoma of the brain</title>
		    <link>https://foliamedica.bg/article/147984/</link>
		    <description><![CDATA[
					<p>Folia Medica 67(6): e147984</p>
					<p>DOI: 10.3897/folmed.67.e147984</p>
					<p>Authors: Asen Cekov, Vladimir Nakov, Anastas Kanev, Ivan Tarev</p>
					<p>Abstract: Abstract     Intracranial germ cell tumors are relatively rare. They can affect the pineal region of the brain or the suprasellar area, or both simultaneously, and can cause various complications as well as endocrinological disorders. These tumors are characterized by their aggressive behavior and the tendency to metastasize.     Intracranial germ cell tumors require an interdisciplinary approach in order to determine the most appropriate management. Radiotherapy and chemotherapy form the backbone of treatment strategies. Surgical methods are not the standard of care for this type of pathology, but they can provide histological confirmation in cases where tumor markers are not significant and can also be considered when seeking immediate symptomatic control.     This study presents a juvenile case of a bifocal primary brain germinoma in which a liver metastasis was found after initial brain surgery and radiation therapy. The complex treatment continued with liver metastasectomy and chemotherapy, with the result of a complete therapeutic response and no recurrence after more than seven years of follow-up.</p>
					<p><a href="https://foliamedica.bg/article/147984/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/147984/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/147984/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Thu, 18 Dec 2025 10:36:38 +0000</pubDate>
		</item>
	
		<item>
		    <title>Acute kidney injury after high-dose methotrexate application – case report</title>
		    <link>https://foliamedica.bg/article/143221/</link>
		    <description><![CDATA[
					<p>Folia Medica 67(5): e143221</p>
					<p>DOI: 10.3897/folmed.67.e143221</p>
					<p>Authors: Petya Markova, Mariya Spasova, Neofit Spasov, Stoyan Markov</p>
					<p>Abstract: Methotrexate, administered in high doses, is utilized in the treatment of a range of childhood cancers. Despite the implementation of routine supportive measures, including intensive hydration, urine alkalinization, and antidote therapy, nephrotoxicity remains a significant problem. The literature suggests a range of frequencies from 1.8% to 36%, depending on the diagnostic method employed. The primary pathogenetic mechanism of its occurrence is the precipitation of methotrexate and its metabolites in the renal tubules, clinically manifesting as crystalline nephropathy, which leads to delayed excretion of the medication. The risk factors, long-term renal prognosis, and safety of re-administration of high-dose methotrexate after an episode of acute kidney injury remain unclear. In the event of nephrotoxicity, restriction of its further use and substitution with another cytostatic drug are often considered. The following clinical case is presented: a 13-year-old girl with osteosarcoma was administered high-dose methotrexate, resulting in fourth-degree acute kidney injury. This necessitated a renal replacement therapy. Given its pivotal role in osteosarcoma treatment, subsequent courses were planned with gradually increasing doses. Four additional courses of high-dose methotrexate were administered at doses of 3 g/m2, 8 g/m2, and 12 g/m2, until the maximum tolerable dose of 20 grams was reached. These courses were well tolerated, with no evidence of toxicity, and the medication was eliminated in a timely manner.</p>
					<p><a href="https://foliamedica.bg/article/143221/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/143221/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/143221/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Thu, 30 Oct 2025 10:00:17 +0000</pubDate>
		</item>
	
		<item>
		    <title>Inflammation biomarkers as predictors of nodal metastases in colorectal cancer</title>
		    <link>https://foliamedica.bg/article/154005/</link>
		    <description><![CDATA[
					<p>Folia Medica 67(5): e154005</p>
					<p>DOI: 10.3897/folmed.67.e154005</p>
					<p>Authors: Ilektra Kyrochristou, Georgios Anagnostopoulos, Ilias Giannakodimos, Konstantina Psalla, Athanasios Rogdakis</p>
					<p>Abstract: Abstract                Aim: The role of chronic inflammation in the genesis and promotion of cancer has been established lately by various researchers. The neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and CRP-to-albumin ratio, and their diagnostic and prognostic significance, are currently under review. The current paper presents a preliminary study on the Greek population of patients suffering from Colorectal Cancer (CRC) to test the correlation between the inflammation markers and the possibility of nodal metastases.           Materials and methods: Retrospective study of all patients treated surgically for CRC in our Surgical Department during the period 2018-2021. We categorized patients as elective and complicated cases, urgently leading to the operating room. We calculated the preoperative neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and CAR (CRP/albumin ratio) of the two groups. The primary endpoint of this study was the evaluation of the prognostic significance of NLR, PLR, and CAR as markers predictive of nodal metastases. Secondary endpoints were the set of cut-off values for each of these markers in the elective and emergency groups.           Results: Overall, 131 patients were included in the study, 89 of whom were treated electively. For all the biomarkers, statistically significant differences were detected between the elective and the emergency surgery groups. The only marker that was found to have prognostic significance on the nodal status was the CAR value, with a cut-off value calculated at 4.7 [sensitivity (61.82%) and specificity (66.67%)].           Conclusion: The inflammation markers previously proved to be related to CRC differ between patients treated electively and urgently. Better categorization of patient populations should be used to get more accurate results. CAR seems to be able to predict nodal metastases preoperatively. Further large-scale studies are needed to validate our results.</p>
					<p><a href="https://foliamedica.bg/article/154005/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/154005/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/154005/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Wed, 22 Oct 2025 20:07:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Assessing diagnostic delay in Ewing sarcoma: A single tertiary center analysis</title>
		    <link>https://foliamedica.bg/article/153324/</link>
		    <description><![CDATA[
					<p>Folia Medica 67(4): e153324</p>
					<p>DOI: 10.3897/folmed.67.e153324</p>
					<p>Authors: Yordan S. Ivanov, Ivo V. Ivanov, Karina A. Atanasova-Ivanova</p>
					<p>Abstract: Introduction: Ewing sarcoma is a rare and highly aggressive primary malignant bone tumor. Early diagnosis is difficult, especially in the early stages of the disease, which often results in delays in diagnosis.           Aim: The aim of this study was to determine the extent of diagnostic delays in patients with Ewing sarcoma in Bulgaria and their relationship with clinical and demographic factors.           Materials and methods: This study examined 40 patients diagnosed and treated with Ewing sarcoma at a single tertiary care unit in Sofia, Bulgaria. The cohort consisted of 26 males and 14 females with a mean age of 18 years (range 6–36 years). We assessed the following patient criteria: time from initial symptoms to final histologic diagnosis; first doctor visit; diagnostic procedures performed at the first doctor visit; and treatment conducted before histologic diagnosis. We performed statistical analyses of the data using a t-test, chi-squared test, and logistic regression analysis.           Results: The mean diagnostic delay for our patients was 182 days (range 30–730 days), or approximately six months. Statistical analysis revealed that the diagnostic delay did not have a statistically significant effect on overall patient survival (p&gt;0.05). Of all the analyzed variables, only tumor stage had a statistically significant impact on overall survival.           Conclusion: Patients with Ewing sarcoma in Bulgaria experience a significant diagnostic delay, highlighting issues in the disease’s diagnostic process. However, diagnostic delay did not significantly impact overall survival, suggesting that tumor biology and stage are more critical prognostic factors.</p>
					<p><a href="https://foliamedica.bg/article/153324/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/153324/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/153324/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Fri, 29 Aug 2025 22:55:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Reference values of human epididymis protein 4 in the Bulgarian population – assessment of the influence of age, menopause, pregnancy, and renal function</title>
		    <link>https://foliamedica.bg/article/155013/</link>
		    <description><![CDATA[
					<p>Folia Medica 67(4): e155013</p>
					<p>DOI: 10.3897/folmed.67.e155013</p>
					<p>Authors: Vesselina Koleva-Topova, Sevim Shefket</p>
					<p>Abstract: Introduction: Human epididymis protein 4 (HE4) is increasingly utilized in diagnosing pelvic masses and monitoring patients with ovarian or endometrial carcinoma. However, various publications and diagnostic kit manufacturers report a wide range of reference and threshold values, complicating accurate clinical interpretation and reducing the marker’s clinical utility. This study aimed to establish reference values for HE4 in the Bulgarian female population and investigate the impact of physiological factors such as age, menopause, and pregnancy, as well as pathological conditions like impaired renal function, on marker levels.           Materials and methods: The study included 338 women: 246 healthy, nonpregnant women aged 20–82 (124 of whom were premenopausal); 52 pregnant women; and 40 women with reduced renal function, as determined by serum creatinine levels. Data were collected on gynecological status, renal and hepatic function, diabetes, and other clinically significant chronic or oncological diseases. Serum HE4 concentrations were measured using an indirect chemiluminescent microparticle immunoassay (CMIA) on the Architect ci8200 system (Abbott Diagnostics). Statistical analyses were performed using SPSS version 25.0, and values were considered statistically significant at p&lt;0.05.           Results: The upper reference limit for HE4 in healthy women (95th percentile with 95% confidence interval) was 62.43 (59.02–65.45) pmol/L. For menopausal status, upper reference limits were 53.22 (50.80–60.82) pmol/L for premenopausal women and 65.31 (61.57–68.35) pmol/L for postmenopausal women. In pregnant women, the upper HE4 limit was 50.90 pmol/L, with values by gestational age of 57.73 pmol/L (first trimester) and 46.35 pmol/L (second trimester). None of the women with serum creatinine within the reference range had elevated HE4 levels, whereas all patients with elevated creatinine had HE4 levels above the 95th percentile for their respective age and menopausal status.           Conclusions: The established reference limits for HE4 in this study significantly differ from those proposed by Abbott Diagnostics that are used to date. Implementing these limits in clinical practice could enhance the marker’s sensitivity and enable earlier detection of gynecological malignancies. The data confirm that HE4 levels depend on age, particularly after 60 years, and on reduced renal function, necessitating cautious interpretation in these patients. No significant differences in HE4 concentrations were observed between pregnant and non-pregnant women, supporting the use of uniform reference values regardless of pregnancy or gestational stage.</p>
					<p><a href="https://foliamedica.bg/article/155013/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/155013/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/155013/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Fri, 29 Aug 2025 18:23:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Orthoplastic approach to limb salvage surgery in oncology: types of flaps and surgical timing</title>
		    <link>https://foliamedica.bg/article/145385/</link>
		    <description><![CDATA[
					<p>Folia Medica 67(4): e145385</p>
					<p>DOI: 10.3897/folmed.67.e145385</p>
					<p>Authors: Michela Saracco, Maria Grazia Cerrone, Gianmarco Vavalle, Raffaele Vitiello, Omar El Ezzo, Giulio Maccauro, Elisabetta Pataia</p>
					<p>Abstract: Extremities are a very common site for the development of malignant tumors. A multidisciplinary approach is essential for the proper management of extremity tumors, ensuring complete surgical resection with clear margins, proper management of tissue loss, and optimal functional recovery following reconstruction. Up to 95% of patients undergo successful limb-sparing treatments, avoiding amputation. We will discuss the advantages and disadvantages of using various flaps to reconstruct upper and lower extremities. We will also explore the applications of microvascular surgery and free flaps in this context and conclude with a reflection on the timing of reconstructions.</p>
					<p><a href="https://foliamedica.bg/article/145385/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/145385/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/145385/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Invited Review</category>
		    <pubDate>Fri, 15 Aug 2025 22:45:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Diagnostic accuracy of CRP in the drainage fluid for early detection of anastomotic leakage in colorectal surgery – a pilot study</title>
		    <link>https://foliamedica.bg/article/154087/</link>
		    <description><![CDATA[
					<p>Folia Medica 67(4): e154087</p>
					<p>DOI: 10.3897/folmed.67.e154087</p>
					<p>Authors: Ilektra Kyrochristou, Georgios Anagnostopoulos, Konstantina Psalla, Panagiotis Giannakakis, Athanasios Rogdakis</p>
					<p>Abstract: Introduction: Anastomotic leak (AL) in colorectal surgery remains a source of concern, as it jeopardizes patient recovery and increases morbidity, particularly if not detected early. The CRP in the drain fluid has barely been investigated as a new predictive marker of AL that would improve treatment outcomes.           Materials and methods: A prospective pilot study conducted in our department included patients undergoing emergency colorectal surgery and primary anastomosis for benign and malignant disease. The CRP values of the drainage fluids and serum were measured on postoperative day 3 (POD3). The preoperative levels of albumin were also measured. Patients were followed for 2 months after their surgery, for the presence of clinical or subclinical AL. The accuracy of the CRP in the drain on POD3 to predict the incidence of AL was investigated. Secondary outcomes included the relation of the drain’s CRP to that of the serum and the incidence of AL in patients with low preoperative albumin levels.           Results: Of the 188 patients who were treated for malignant and benign diseases of the small and large bowel, 56 were included in the study, 12 of whom were found to have an anastomotic leak. The estimated average C-reactive protein (CRP) level in drain fluid on postoperative day 3 (POD3) was significantly higher in the anastomotic leak (AL) group (t-test, t=−6.969, p&lt;0.001). After examining the ROC curves, we defined a cut-off value for drain CRP of 77.65 mg/dL. This value demonstrated 91.7% sensitivity and 90.9% specificity in predicting AL. Furthermore, the odds of AL increased by 10.9% (95% CI [4.4%, 17.7%]) with each additional unit of CRP measured in the drain fluid.           Conclusions: Maintaining a simple and cheap-to-measure prognostic factor of AL would be valuable in diminishing the devastating results of delayed leak identification. The CRP in the drain fluid seems a significant prognostic marker. We hope that the inclusion of more patients will confirm our results and highlight their significance.</p>
					<p><a href="https://foliamedica.bg/article/154087/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/154087/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/154087/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Thu, 14 Aug 2025 22:32:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Cholesteatoma: diagnosis, management and follow-up, and an interesting case report</title>
		    <link>https://foliamedica.bg/article/140847/</link>
		    <description><![CDATA[
					<p>Folia Medica 67(4): e140847</p>
					<p>DOI: 10.3897/folmed.67.e140847</p>
					<p>Authors: Aikaterini Lianou, Magdalini Bizoglou, Dimitra Simou, Georgios Psychogios</p>
					<p>Abstract: Cholesteatomas are benign tumors composed of skin-related substances. They can extensively infiltrate the ear and compromise surrounding structures, requiring surgical removal. Computed tomography can assist with surgical planning by illustrating the position and impact of the cholesteatoma. Recent advancements in magnetic resonance imaging have demonstrated enhanced visualization of cholesteatomas. Whereas additional surgical intervention was formerly necessary to identify cholesteatoma recurrence, magnetic resonance imaging can now often serve as an alternative. This paper reviews the current evidence on diagnosing, managing, and following up with patients with cholesteatoma. It also presents an interesting case that highlights the value of diffusion-weighted imaging (DWI), even in cases of initial diagnosis.</p>
					<p><a href="https://foliamedica.bg/article/140847/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/140847/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/140847/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Thu, 14 Aug 2025 22:23:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>The use of coblation technique for the debulking of juvenile angiofibroma</title>
		    <link>https://foliamedica.bg/article/142588/</link>
		    <description><![CDATA[
					<p>Folia Medica 67(4): e142588</p>
					<p>DOI: 10.3897/folmed.67.e142588</p>
					<p>Authors: Evangelos Giotakis, Vasileios Ragos, Aris Giotakis, Aris Papapetropoulos, Panagiotis Chadoulos, Aikaterini D. Lianou</p>
					<p>Abstract: In this paper, we describe how we successfully debulked a large juvenile nasopharyngeal angiofibroma (JNA) in a 15-year-old boy using the coblation technique. The child had been complaining about recurrent epistaxis and persistent nasal obstruction for several months. JNA is a rare benign tumor that predominantly affects adolescent and young adult males. JNAs exhibit gradual progression, local expansion, high vascularity, and a notable tendency for persistence and recurrence. Due to their high vascularity, JNAs require surgical removal, and treatment commonly includes preoperative embolization and endoscopic methods. Complete tumor resection is the gold standard treatment. Tumor manipulation can lead to substantial bleeding due to its rich blood supply and lack of surface muscle fibers. Using the coblation technique for tumor debulking offers distinct advantages, including better control of blood loss, reduced thermal damage, improved visibility of the surrounding area, better postoperative recovery, and less resection of vital anatomical structures.</p>
					<p><a href="https://foliamedica.bg/article/142588/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/142588/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/142588/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Thu, 14 Aug 2025 18:07:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Prognostic factors and survival of recurrent glioblastoma: a systematic review</title>
		    <link>https://foliamedica.bg/article/142227/</link>
		    <description><![CDATA[
					<p>Folia Medica 67(3): e142227</p>
					<p>DOI: 10.3897/folmed.67.e142227</p>
					<p>Authors: Renindra Aman, Fitrie Desbassarie, Altair Rahman Lubis, Irfani Ryan Ardiansyah</p>
					<p>Abstract: Introduction: Glioblastoma is a highly aggressive brain cancer with poor prognosis. Recurrence is common, and survival post-recurrence is limited. Identifying prognostic factors for recurrent glioblastoma can optimize treatment and improve outcomes.           Aim: This systematic review analyzed the clinical, molecular, and treatment-related variables that influence survival in patients with recurrent glioblastoma.           Materials and methods: A comprehensive search of PubMed, Scopus, and ProQuest databases included studies from the past decade, assessed using the Newcastle-Ottawa Scale (NOS).           Results: Sixteen studies were analyzed, highlighting age, Karnofsky Performance Status (KPS), molecular markers (MGMT promoter methylation, IDH mutations, TERT promoter mutations, TP53 alterations, ATRX loss, and Ki-67 expression), and surgical resection extent as key prognostic factors. Younger patients with higher KPS scores and favorable molecular markers had better survival. Molecular profiling and maximal resection correlated with improved overall survival (OS). Salvage therapies like chemotherapy and re-resection provided marginal benefits, with variability based on patient demographics and tumor genetics.           Conclusion: Age, KPS, molecular markers, and surgical resection extent significantly predict survival in recurrent glioblastoma. The review underscores the importance of molecular profiling for personalized treatment, though current salvage therapies show limited effectiveness. Innovative approaches are needed to enhance outcomes for this aggressive disease.           Abbreviations used in the article: BSC: best supportive care; CRE: complete resection of enhancing tumor; DFS: disease-free survival; GBM: glioblastoma; GTR: gross total resection; KPS: Karnofsky Performance Status; NOS: Newcastle-Ottawa Scale; OS: overall survival; PFS: progression-free survival; rGBM: recurrent glioblastoma multiforme; RTOG–RPA: Radiation Therapy Oncology Group – Recursive Partitioning Analysis; TTF: tumor-treating fields</p>
					<p><a href="https://foliamedica.bg/article/142227/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/142227/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/142227/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Fri, 6 Jun 2025 11:14:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Digit-sparing surgery for hand bone tumors: results of en-bloc bone resection and repla cement with osteoarticular allografts</title>
		    <link>https://foliamedica.bg/article/147939/</link>
		    <description><![CDATA[
					<p>Folia Medica 67(2): e147939</p>
					<p>DOI: 10.3897/folmed.67.e147939</p>
					<p>Authors: Lorenzo Andreani, Martina Cordoni, Elena Bechini, Fabrizia Gentili, Andrea De Blasi, Antonio D'Arienzo, Edoardo Ipponi, Paolo Domenico Parchi</p>
					<p>Abstract: Abstract                Introduction: The treatment of malignant bone tumors in the hand should be focused on the complete removal of the neoplasm. Thereby, amputation of the involved digital ray or even the whole hand is often necessary. However, a ray-sparing approach could be sufficient to eradicate locally aggressive and low-grade malignant tumors confined to the bone.           Aim: We present our experience with en-bloc resection of long bones of the hand and their replacement with osteoarticular allografts.           Materials and methods: We evaluated all our cases with locally aggressive low-grade bone tumors of the hand, treated with a whole-bone en-bloc resection and replaced with an osteoarticular allograft. Intraoperative and postoperative complications were recorded. Patients’ preoperative and postoperative functionality was assessed with the MSTS score and eventual post-operative digital ray stiffness was classified using the Tubiana classification.           Results: Five patients were included in our study (1 metacarpal, 3 proximal, and 1 middle phalanx). Cases had grade 1 CS (3), GCT of the bone (1), or Gorham-Stout disease (GSD; 1). The mean FU was 19 months.     The patient with GSD (middle phalanx) had a local recurrence and underwent ray amputation. The patient treated in his metacarpal bone had a slight finger rotation (about 5°), but no stiffness. The three cases treated with proximal phalanx allografts were Tubiana 1A (1) or 1B (2). The mean MSTS score was 26.4.           Conclusions: A digit-sparing surgery, performed with a whole-bone en-bloc resection and the implant of an osteoarticular allograft, could represent a solution for selected cases with locally aggressive and low-grade malignant tumors of the long bones in the hand.</p>
					<p><a href="https://foliamedica.bg/article/147939/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/147939/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/147939/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Fri, 11 Apr 2025 21:41:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Transfusion frequency, ferritin, and carotid intima media thickness in transfusion-dependent thalassemia patients</title>
		    <link>https://foliamedica.bg/article/143457/</link>
		    <description><![CDATA[
					<p>Folia Medica 67(2): e143457</p>
					<p>DOI: 10.3897/folmed.67.e143457</p>
					<p>Authors: Rahmat Cahyanur, Muhammad Ikhsan, Shabrina Tadjoedin, Devi Nurfadila Fani</p>
					<p>Abstract: Introduction: The carotid tunica intima-media thickness (cIMT) is an early marker of atherosclerosis and associated with an increased risk of cardiovascular diseases. Endothelial dysfunction also contributed with the increased cardiovascular risk in thalassemia caused by iron accumulation, reduced nitric oxide, and increased lipid peroxidation. Studies about atherosclerosis markers in thalassemia patients show inconsistent results.           Aim: This research assesses cIMT in transfusion-dependent thalassemia patients and examines its relationship with clinical and laboratory parameters.           Materials and methods: This was a cross-sectional study that was conducted from March to May 2024, in the Therapy and Thalassemia Clinics, Universitas Indonesia Hospital. Ultrasound cIMT measurements were recorded for both the left and right distal common carotid artery walls, 5 mm proximal to the bifurcation. The cIMT diameters were collected from each wall and mean thickness values from both sides.           Results: This study included 25 adult thalassemia patients who were diagnosed with transfusion-dependent thalassemia. Most subjects were male, with a median age of 25 years, and had an underweight BMI. Patients with underweight BMI had thicker cIMT, both in mean and maximum diameter (p=0.008 and p=0.011, respectively).           Conclusion: Additionally, a transfusion frequency of ≥3 per month had a greater maximum diameter cIMT (p=0.046). A moderate positive correlation was observed between average ferritin levels and maximum intima-media thickness (r=0.402, p=0.046).</p>
					<p><a href="https://foliamedica.bg/article/143457/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/143457/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/143457/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Fri, 4 Apr 2025 16:19:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Investigations on the dysregulated genes in high-fat-fed mice infected with Prevotella intermedia and their possible role in the development of hepatocellular carcinoma</title>
		    <link>https://foliamedica.bg/article/143604/</link>
		    <description><![CDATA[
					<p>Folia Medica 67(2): e143604</p>
					<p>DOI: 10.3897/folmed.67.e143604</p>
					<p>Authors: Yathin Reddy Putta, Anitha Pandi, Jayaseelan Vijayashree Priyadharsini</p>
					<p>Abstract: Introduction: Hepatocellular carcinoma (HCC) is a leading global cancer, often linked to various factors, including viral infections and metabolic disorders. Recent studies suggest that microbial infections, particularly from oral pathogens like Prevotella intermedia (Pi), may elevate the progression of HCC through dysbiosis and chronic inflammation.           Aim: In view of this, the study aimed to identify candidate genes in high-fat diet-fed mice infected with Pi and to assess the relevance of these orthologous genes in the development of human HCC.           Materials and methods: The GEO dataset, GSE136937, was employed to identify the differentially expressed genes across two datasets viz., regular chow-fed and high-fat diet-fed mice infected with Pi. A comparison was made between normal vs. high-fat diet-fed mice infected with Pi to demonstrate the influence of the microbial factor on the development of metabolic disorders and cancer. The identified DEGs were subjected to protein-protein interaction (PPI) analysis and gene ontology (GO) assessments. Human orthologs were evaluated for gene expression status and survival using the TCGA dataset.           Results: The analysis revealed numerous DEGs between infected and uninfected groups. The top 20 DEGs (16 upregulated, 4 downregulated) were further investigated in liver hepatocellular carcinoma patients (TCGA). Notably, genes RMND1 and CYP3A43 displayed similar expression patterns in both mouse and human datasets. High RMND1 expression was associated with poor prognosis, while low CYP3A43 expression indicated a poor survival outcome in HCC patients.           Conclusion: Metabolic disorders in conjunction with microbial dysbiosis together could support the malignant phenotype by modifying the expression profiles of key genes involved in carcinogenesis. More intense experimental and in vivo studies are needed to further confirm the association of these candidate genes with HCC.</p>
					<p><a href="https://foliamedica.bg/article/143604/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/143604/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/143604/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Fri, 4 Apr 2025 10:55:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Adrenocortical carcinoma with dual androgen and cortisol secretion</title>
		    <link>https://foliamedica.bg/article/130505/</link>
		    <description><![CDATA[
					<p>Folia Medica 67(1): e130505</p>
					<p>DOI: 10.3897/folmed.67.e130505</p>
					<p>Authors: Areti Kalfoutzou, Pantelis Petroulakis, Adam Mylonakis, Asimina Restemi, Nikolaos Chaleplidis, Eleni Anagnou, Georgios Tsikalakis, Margaritis Tsantopoulos, Eleni Mostratou</p>
					<p>Abstract: Adrenocortical carcinoma (ACC) is a rare endocrine cancer that originates in the adrenal cortex, known for its capacity to produce hormones such as cortisol, aldosterone, estrogens, or androgens. These hormonal imbalances lead to a diverse array of clinical manifestations. This case report describes a middle-aged male patient presenting with a dual-hormone secreting ACC, characterized by the secretion of both androgens and cortisol. This hormonal profile resulted in Cushing syndrome along with symptoms of androgen excess, including bilateral lower limb edema, prolonged fatigue, and altered mental status. An extensive diagnostic evaluation, including clinical assessments, laboratory tests and imaging revealed the presence of an adrenal mass and lung metastases. Imaging-guided biopsy confirmed diagnosis of ACC with simultaneous androgen and cortisol secretion. This report enriches the sparse literature on dual-secreting ACC, highlighting the complexities in its diagnosis and management.</p>
					<p><a href="https://foliamedica.bg/article/130505/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/130505/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/130505/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Wed, 26 Feb 2025 09:49:37 +0000</pubDate>
		</item>
	
		<item>
		    <title>Clinical significance of human epididymis protein 4 (HE4), cancer antigen 125 (CA125), the risk of ovarian malignancy algorithm (ROMA), and Copenhagen index (CPH-I) for the diagnosis of endometrial carcinoma</title>
		    <link>https://foliamedica.bg/article/143849/</link>
		    <description><![CDATA[
					<p>Folia Medica 67(1): e143849</p>
					<p>DOI: 10.3897/folmed.67.e143849</p>
					<p>Authors: Vesselina Koleva, Sevim Shefket, Snezhana Stoencheva</p>
					<p>Abstract: Introduction: Endometrial carcinoma (EC) is the most common gynecological cancer among women, and in more than 90% of cases, the initial manifestation of the disease is postmenopausal bleeding. Unfortunately, despite early diagnosis and treatment, EC often recurs. Among the many serum tumor markers studied, human epididymis protein 4 (HE4) and cancer antigen 125 (CA125) show the most promise as tools for EC diagnosis, prognosis, and monitoring.           Aim: The aim of the current study was to evaluate the clinical usefulness of HE4 and CA125, tested either as single markers or in combination by including them in the Risk of Ovarian Malignancy Algorithms (ROMA) and in Copenhagen index (CPH-I).           Material and methods: In this retrospective study, 1262 women (74 with confirmed EC) were included. The patients with EC had significantly higher values for HE4, CA125, ROMA, and CPH-I (p&lt;0.001) than the healthy women and patients with benign diseases. The subgroup analysis based on the histological type of EC revealed that the highest markers and algorithms were recorded in type II EC group.           Results: The ROC curve analysis showed that the best diagnostic performance for detecting EC among patients with benign diseases was the ROMA index (AUC=0.869; 95% CI: 0.818-0.920), followed by CPH-I (AUC=0.822; 95% CI: 0.757-0.887), and HE4 (AUC=0.816; 95% CI: 0.750-0.881). Tested alone, CA125 presented unsatisfactory results for this purpose. Both algorithms proved to have a correlation with the disease stage and progression better than the markers alone (HR=1.046 vs. HR=1.018).           Conclusion: In summary, the ROMA index, CPH-I, and, to a lesser extent, standalone HE4 testing can supplement imaging methods as reliable tools for diagnosing and distinguishing patients with EC from those with benign conditions. They have potential as prognostic markers for advanced disease and could help gynecological oncologists to develop a therapeutic strategy.</p>
					<p><a href="https://foliamedica.bg/article/143849/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/143849/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/143849/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Tue, 25 Feb 2025 08:58:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Synchronous local recurrence and liver metastasis from extragastrointestinal stromal tumor in the rectovaginal septum: a unique case presentation</title>
		    <link>https://foliamedica.bg/article/125700/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(6): 923-928</p>
					<p>DOI: 10.3897/folmed.66.e125700</p>
					<p>Authors: Eleni Papamattheou, Ioannis Katsaros, Eirini Chorianopoulou, Kyriaki Theodorolea, Gabriela Stanc, Christos Iavazzo, Elissaios Kontis</p>
					<p>Abstract: The rectovaginal septum is a rare location for gastrointestinal stromal tumors (GIST) to occur. The aim of this study was to present a case of synchronous local recurrence of solitary liver metastasis originating from an extra gastrointestinal tumor (E-GIST) of the rectovaginal space.     A 55-year-old woman, with a medical history of a resected meningioma, was referred to our department due to a 5 cm solitary liver metastasis located within the left lateral segment. The patient had undergone a transvaginal resection of a low-risk E-GIST 6 months prior without receiving adjuvant chemotherapy. The patient underwent a synchronous laparoscopic left lateral hepatectomy and a transvaginal resection with posterior vaginal wall reconstruction. Her postoperative course was uneventful and was discharged on the fifth postoperative day. The histological examination of the vaginal lesion revealed the development of neoplasm with pathological characteristics consistent with the initial histology expect for a mitotic index exceeding &gt;20%. Liver histology report also included a high-risk GIST with CKIT (+), DOG1 (+), ki67 ≥30%, high mitotic activity and clear resection margins. The patient was referred for adjuvant chemotherapy.     E-GISTs are rare neoplasms with low malignant potential. However, these tumors may exhibit metastatic potential and require aggressive treatment.</p>
					<p><a href="https://foliamedica.bg/article/125700/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/125700/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/125700/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Tue, 31 Dec 2024 12:56:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>A case of extraskeletal chondroma in the left inguinal region</title>
		    <link>https://foliamedica.bg/article/126111/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(6): 917-922</p>
					<p>DOI: 10.3897/folmed.66.e126111</p>
					<p>Authors: Alexey Shabunin, Ivan Lebedinsky, David Dolidze, Zurab Bagatelia, Ekaterina Solomonova, Anna Bumbu, Serghei Covantsev</p>
					<p>Abstract: Extraskeletal chondromas are rare benign neoplasms comprising mature hyaline cartilage. A distinctive feature of these tumors is that they develop in soft tissues away from bone and cartilage. Extraskeletal chondromas account for 1.5% of benign soft tissue tumors. They occur predominantly at 30-60, in males, and in the hand or foot. In only 4% of cases, the tumor is located not on the extremities. Patients predominantly complain of increased mass, rarely on pain or a pulling sensation. The literature on the chondromas of the anterior abdominal wall is scarce. We present a rare case of a large extraskeletal left inguinal chondroma in a 71-year-old patient. The mass was over 6 cm large, and this is the only case of inguinal chondroma described in the literature. The mass was resected with surrounding tissues (a surgical margin of 1 cm) under combined endotracheal anesthesia and the histology confirmed the tumor to be a chondroma.</p>
					<p><a href="https://foliamedica.bg/article/126111/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/126111/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/126111/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Tue, 31 Dec 2024 12:56:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Sentinel lymph nodes biopsy for malignant tumors using Technefit radioactive colloid Technetium 99mTc</title>
		    <link>https://foliamedica.bg/article/134377/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(6): 895-904</p>
					<p>DOI: 10.3897/folmed.66.e134377</p>
					<p>Authors: Irina Onofriychuk, Aziz Zikiryahodzhaev, Anatoliy Ermakov, Nataliya Ablitsova, Eric Saribekyan, Elena Rasskazova, Gadgimurad Zapirov, Stanislav Mikhailov, Andrey Kaprin, Anna Sukhotko, Serghei Covantsev</p>
					<p>Abstract: Introduction: Technetium-99m (99mTc) is a short-lived nanocolloid nuclide widely used by oncologists to diagnose and identify cancer dissemination.           Aim: The aim of the current study was to develop the technique of radiopharmaceutical preparation (RPP) of Technefit99mTc aimed at examining sentinel lymph nodes (SLN) before surgery.           Materials and methods: We performed a series of trials (33 patients). Based on the information obtained from the portable gamma detector NEO2000 during surgery, a biopsy of the sentinel lymph nodes was carried out when RPP Technefit 99mTc accumulated in a specific lymph node.           Results: We determined maximum activities, volume, and peculiarities of administration of radioactive colloid Technefit99mTc in order to examine and perform the biopsy of SLN in the patients with malignant tumors. The most informative results in terms of scintigraphy images of sentinel lymph nodes were revealed in the first trial of the research, with all 5 cases (100%) showing positive results. The first trial included Technefit intradermal-hypodermal injection into one point above the tumor node, RPP activity of 75 to 200 mBq at a room temperature of 21°C, without preliminary anesthesia with Novocain solution.           Conclusion: We determined the most efficient dosages of activities, volume, and characteristics of radioactive colloid administration aimed at the examination and biopsy of sentinel lymph nodes using the radiopharmaceutical preparation Technefit 99mTc in patients with malignant tumors of different localizations, namely breast cancer and skin melanoma. In some cases, we did not find any signs of considerable lowering of the Technefit 99mTc activity, which shows that there is a very slow filtration of Technefit 99mTc through the pores of lymph capillaries.</p>
					<p><a href="https://foliamedica.bg/article/134377/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/134377/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/134377/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Tue, 31 Dec 2024 12:56:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Retrospective study of post-treatment 131I SPECT/CT imaging for personalizing therapy of patients with differentiated thyroid cancer</title>
		    <link>https://foliamedica.bg/article/139177/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(6): 776-786</p>
					<p>DOI: 10.3897/folmed.66.e139177</p>
					<p>Authors: Sonya Sergieva, Teodor Sofiyanski, Bozhil Robev, Milena Dimcheva, Albena Fakirova</p>
					<p>Abstract: Introduction: The absence of anatomical landmarks in the whole body scan makes it challenging to precisely localize 131I uptake, which is used to treat patients with differentiated thyroid cancer (DTC). Recently, SPECT/CT studies have been utilized to increase the diagnostic sensitivity and specificity.           Aim: To evaluate the clinical role of post-treatment 131I SPECT/CT imaging in the management of DTC.           Materials and methods: The study included 564 patients (384 women and 180 men) aged 12 to 83 years with DTC referred to our hospital between 2011 and 2021. A post therapeutic 131I whole-body scintigraphy (WBS) with SPECT/CT imaging was performed.           Results: 370 (65%) cases with papillary carcinoma, 101 (18%) cases with follicular carcinoma, and 93 (17%) cases with follicular variant of papillary DTC were histologically proven. 131I WBS was positive in 423 (75%) cases. SPECT/CT showed thyroid remnant in 237 (42%) patients, tumor persistence – in 15 (2.7%), and local recurrence in the thyroid bad in 17 (3%) cases. Enlarged cervical and mediastinal lymph nodes were visualized in 141 (25%) cases. Forty-eight (8.5%) patients had pulmonary metastases, 14 had osteolytic bone lesions and 6 (1.4%) had brain metastases detected on the SPECT/CT images. Negative 131I SPECT/CT data influenced significantly the clinical management of a large cohort with recurrent and metastatic DTC, leading to rejection of radioiodine treatment as a therapeutic alternative.           Conclusion: SPECT/CT improved the 131I WBS accuracy, thus changing the management of DTC determining indications for surgery, the need to give or withhold 131I therapy, and selecting cases for radiotherapy or chemotherapy in order to personalize the treatment.</p>
					<p><a href="https://foliamedica.bg/article/139177/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/139177/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/139177/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Tue, 31 Dec 2024 12:56:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Giant dorsal liposarcoma in an elderly man: a case report</title>
		    <link>https://foliamedica.bg/article/125471/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(5): 749-754</p>
					<p>DOI: 10.3897/folmed.66.e125471</p>
					<p>Authors: Daniela Arias-Mariño, Alejandro Rojas-Urrea, Diego Herrera-Salcedo, Lorena García-Agudelo</p>
					<p>Abstract: Liposarcoma is a malignant mesenchymal tumor defined as a rare cancer due to its low incidence rate. The most common location of liposarcoma is in the extremities, followed by retroperitoneum, with the bone and trunk being the less frequent presentations. The most common histological subtype is well-differentiated liposarcoma, which has the highest local recurrence, is slow-growing, and is insensitive to chemo and radiotherapy. We present the case of a 62-year-old male patient with a 10-year-growth mass in the dorsal region. A computed tomography scan showed a huge mass in the right dorsal space with a malignant lipomatous appearance, which required surgical removal of a mass of 2,800 g.</p>
					<p><a href="https://foliamedica.bg/article/125471/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/125471/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/125471/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Thu, 31 Oct 2024 15:14:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Giant cystic lymphangioma as a rare cause of acute abdomen in infancy: a case report and literature review</title>
		    <link>https://foliamedica.bg/article/124560/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(5): 737-742</p>
					<p>DOI: 10.3897/folmed.66.e124560</p>
					<p>Authors: Chrysovalantis Mariorakis, Eleni Boutouridou, Athanasios Pegios, Vasilki Magaliou, Marianna Polydoridou, Ioannis Georgakis, Elpis Chochliourou, Ilias Chatziioannidis, Elissavet Anestiadou, Georgios Papouis</p>
					<p>Abstract: Lymphangioma, a benign mass of lymphatic origin, primarily affects the head, neck, and oral cavity, with the abdomen being an uncommon location. Clinical presentation is defined by site of origin and size. We present the case of a 10-month-old male infant with no previous medical history, admitted to our department with diffuse abdominal pain and distension. Physical examination revealed a huge, palpable mass arising from the left abdomen, abdominal tenderness, guarding, and rigidity. Abdominal ultrasound revealed a multilocular, non-measurable mass with both cystic and solid components that were suggestive of a giant cystic lymphangioma. Multidetector computed tomography and magnetic resonance imaging were performed to estimate the size and extension of the tumor for preoperative planning. Moreover, an elevated alpha-fetoprotein level further supported the neoplastic origin of the tumor. Exploratory laparotomy was performed, and a mass measuring approximately 13.9×16.7×15.4 cm was identified and completely excised in negative margins. Histopathological findings confirmed the initial diagnosis. Our patient had an uncomplicated postoperative course and recovery, with no signs of recurrence on a 6-month follow-up. Giant abdominal lymphangiomas in infants are extremely rare and close attention for complications is vital. Surgical intervention with complete resection is considered the optimal management.</p>
					<p><a href="https://foliamedica.bg/article/124560/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/124560/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/124560/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Thu, 31 Oct 2024 15:14:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Attitudes and awareness related to cervical cancer vaccine</title>
		    <link>https://foliamedica.bg/article/130668/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(5): 707-716</p>
					<p>DOI: 10.3897/folmed.66.e130668</p>
					<p>Authors: Darina N. Ruschukova, Teodora D. Momchilova, Marieta S. Vladimirova, Zlatina I. Nikolova, Krikor O. Indjian</p>
					<p>Abstract: Introduction: Cervical cancer causes major morbidity and mortality around the world. This makes prophylactic vaccines a significant tool for preventing the disease. As these vaccines become more widely available, they have the potential to drastically lower the cancer’s prevalence and burden in the future.           Aim: The aim of this study was to assess the attitudes toward awareness of the human papillomavirus (HPV) vaccination.           Materials and methods: A pilot, cross-sectional, medicosocial survey was conducted using a structured, anonymous online questionnaire, including self-assessment questions on awareness and attitudes towards HPV vaccination. Sixty-four adult female parents of female children participated in the study between June and August 2023. The design and conduct of the study was done with the personal involvement of the researchers. SPSS v. 23.0 was used to analyze the primary statistical information. The results obtained were presented graphically using MS Excel 2010.           Results: We found significantly good awareness and negative attitude towards vaccination as prevention against HPV.           Conclusion: The present study demonstrated that respondents had a relatively good awareness of cervical cancer, the risk factors associated with the disease, and the virus that causes it. There was a correlation between socio-demographic characteristics and awareness of the study population. The respondents had a certain distrust of the vaccine. The dissatisfaction stemmed from the fact that vaccination was not a substitute for routine cervical screening, was not 100% effective, and did not provide protection against any type of papilloma virus or against pre-existing HPV infections.     The low vaccination coverage in Bulgaria leads the authors to believe that our country urgently needs new strategies and approaches in the fight against cervical cancer, through continuous training of medical personnel, inclusion of immunization programs in school health care, and improved health education and awareness of HPV vaccination among adolescent girls and their parents.</p>
					<p><a href="https://foliamedica.bg/article/130668/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/130668/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/130668/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Thu, 31 Oct 2024 15:14:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Correlating the genetic alterations and expression profile of the TRA2B gene in HNSCC and LUSC</title>
		    <link>https://foliamedica.bg/article/117367/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(5): 673-681</p>
					<p>DOI: 10.3897/folmed.66.e117367</p>
					<p>Authors: Amba Esakki, Anitha Pandi, Smiline A S Girija, Vijayashree Priyadharsini Jayaseelan</p>
					<p>Abstract: Introduction: Transformer (TRA2B) is a serine/arginine-rich (SR)-like protein family that regulates the alternative splicing of several genes in a concentration-dependent manner. Amplification of the TRA2B gene, which codes for TRA2B, occurs in several malignancies, including those of the lung, cervix, head and neck, ovary, stomach, and uterine.           Materials and methods: The present study design follows a computational approach to predict the molecular mechanisms underlying TRA2B alterations in two cancer phenotypes, viz., lung and head and neck squamous cell carcinoma. The genetic alteration in the TRA2B gene was identified using the cBioportal database. The gene expression pattern in both the cancer types and their survival pattern concerning the expression profile was demonstrated using UALCAN. The microRNA targets of the TRA2B gene were identified using the miRDB database.           Results: Genetic alteration was found to be 27% and 48% in HNSCC and LUSC datasets, respectively. The alterations included gene amplification, missense, nonsense, and splice site mutations. The gene expression profile of TRA2B correlated well with the gene amplification demonstrated by patients in both groups. However, the upregulation of TRA2B did not correlate well with the survival profile in LUSC patients. The downregulation of TRA2B markedly affected the survival of HNSCC patients, which can be attributed to the functions of microRNAs targeting TRA2B transcripts.           Conclusion: Although TRA2B was found to be a potential diagnostic marker exhibiting a differential expression pattern for HNSCC, the employability of this gene as a prognostic marker needs more experimentation. Also, the influence of microRNAs on dysregulated gene expression should be considered to gain a better understanding of the underlying molecular mechanisms precipitating the disease.</p>
					<p><a href="https://foliamedica.bg/article/117367/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/117367/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/117367/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Thu, 31 Oct 2024 15:14:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Thoracoabdominal approach to large adrenal tumors – when laparoscopic adrenalectomy is not enough: a retrospective four-year study</title>
		    <link>https://foliamedica.bg/article/130680/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(5): 637-644</p>
					<p>DOI: 10.3897/folmed.66.e130680</p>
					<p>Authors: Konstantinos Tsalis, Orestis Ioannidis, Natalia Antigoni Savvala, Grigorios Gkasdaris, Panagiotis Christidis, Elissavet Anestiadou, Ioannis Mantzoros, Manousos Pramateftakis, Efstathios Kotidis, Nikolaos Ouzounidis, Vasilis Foutsitzis, Savvas Symeonidis, Stefanos Bitsianis, Angeliki Cheva, Stamatios Angelopoulos</p>
					<p>Abstract: Introduction: Laparoscopic adrenalectomy is considered to be the gold standard approach in the field of adrenal surgery. This technique offers advantages of great importance compared to variant laparotomy techniques. Notwithstanding, a technique that needs to be mentioned is the thoracoabdominal approach which facilitates the anatomic exposure of the retroperitoneum, adrenal gland, and great vessels and is strongly recommended for the surgery of large, malignant adrenal tumors.           Aim: The objective of this study is to evaluate the effectiveness and outcomes of the thoracoabdominal approach in adrenal surgery for large adrenal tumors. By presenting our results and experiences, we aim to highlight the advantages of this technique in providing optimal anatomic exposure of the retroperitoneum, adrenal gland, and great vessels, and to establish its role as a viable alternative to laparoscopic adrenalectomy in complex cases.           Materials and methods: We reviewed retrospectively the data of our patients admitted to our Surgical Department and treated surgically with the thoracoabdominal incision, performed by a single surgeon at our tertiary care center, over the period 01/01/20-31/12/23.           Results: All patients had large retroperitoneal masses of varying complexity, requiring maximal surgical exposure. Seventeen patients in total underwent operation with the indication of unilateral adrenal tumor. Five of those patients underwent a laparoscopic tumor resection, while 12 patients were treated by thoracoabdominal approach. Our study group included 7 women (58%) and 5 men (42%), with average age 57 years. The mean maximum tumor diameter was 10.8 cm.           Conclusion: The advantages of the thoracoabdominal approach regarding the exposure of the operative field in challenging cases, together with the low incidence of complications noted in our experience, render this technique an excellent alternative if indicated.</p>
					<p><a href="https://foliamedica.bg/article/130680/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/130680/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/130680/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Thu, 31 Oct 2024 15:14:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Schwannomas of the upper limb: Clinical presentation, preoperative management and outcomes of surgical treatment</title>
		    <link>https://foliamedica.bg/article/135490/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(5): 618-628</p>
					<p>DOI: 10.3897/folmed.66.e135490</p>
					<p>Authors: Edoardo Ipponi, Elena Bechini, Martina Cordoni, Fabrizia Gentili, Francesco Rosario Campo, Fabio Cosseddu, Antonio D’Arienzo, Paolo Domenico Parchi, Lorenzo Andreani</p>
					<p>Abstract: Inroduction: Schwannomas are the most common tumors of the peripheral nervous system. Surgical eradication with excision or enucleation is the treatment for symptomatic and large schwannomas.           Aim: Few studies have investigated the clinical outcomes related to the surgical approach to schwannomas. Our study aims to evaluate the clinical and functional results of surgery for the treatment of upper limb schwannomas.           Materials and methods: Twenty-two cases of upper limb schwannomas were surgically treated in our institution between January 2016 and December 2023. All cases underwent preoperative and 6-month postoperative MRI. For each case, we recorded the diagnostic interval (symptom-diagnosis), symptoms (stenosis or sensory deficits, pain, and Tinel test), and both pre-and postoperative functional status (with DASH and MSTS scores). We also recorded complications and local recurrences.           Results: On average, the diagnosis was made 16.7 months after the onset of the first symptom. The mean preoperative MSTS, DASH, and MRC values were 27.9, 5.7, and 4.8, respectively. We had no intra-operative complications. After a mean follow-up of 43.1 months, MSTS, DASH were 29.7/30 and 0.7, respectively. No case developed local recurrences. No case recorded stenosis deficits at the last follow-up. Only one patient developed local paresthesia (9%), while two reported modest dysesthesias.           Conclusions: An adequate surgical approach, possibly preceded by a rapid diagnosis, can significantly improve the symptoms caused by schwannoma, restoring the functionality of the upper limb.</p>
					<p><a href="https://foliamedica.bg/article/135490/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/135490/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/135490/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Thu, 31 Oct 2024 15:14:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Primary pleomorphic breast sarcoma – a case report</title>
		    <link>https://foliamedica.bg/article/120391/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(4): 568-573</p>
					<p>DOI: 10.3897/folmed.66.e120391</p>
					<p>Authors: Daniel Markov, Petar Uchikov, Pavel Timonov, Galabin Markov, Elena Poryazova</p>
					<p>Abstract: Primary mammary sarcomas are very rare, histologically heterogeneous non-epithelial malignant neoplasms. Primary undifferentiated pleomorphic sarcoma is a rare malignant mesenchymal tumor in the breast. It is characterized by marked cellular atypism and pleomorphism. Isolated cases with an aggressive course and poor prognosis have been commonly described in the literature. We present a rare case of a 62-year-old woman with an 18-cm solid tumor of the left breast, 6 months old, which grew rapidly during the last month. Physical examination and mammography revealed no enlarged lymph nodes in the left axilla. A total mastectomy was performed. The diagnosis of undifferentiated pleomorphic sarcoma is challenging due to the lack of specific immunohistochemical markers. It can only be made after excluding other types of soft tissue sarcomas. This report discusses the histopathological and immunohistochemical studies that were conducted. Our case is distinguished from others with the same diagnosis by the atypical clinical presentation, which is painless, and the spontaneous bleeding, as well as the large size of the tumor.     This malignant tumor is a diagnostic and therapeutic challenge for pathologists, surgeons, and oncologists due to the lack of consensus schemes.</p>
					<p><a href="https://foliamedica.bg/article/120391/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/120391/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/120391/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Sat, 31 Aug 2024 14:50:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Eyelid tumors in children over a 10-year period</title>
		    <link>https://foliamedica.bg/article/123678/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(4): 475-480</p>
					<p>DOI: 10.3897/folmed.66.e123678</p>
					<p>Authors: Georgi Balchev</p>
					<p>Abstract: Introduction: Eyelid tumors in children are rare and, fortunately, mostly benign. Reconstruction after excision of these tumors is an extremely responsible procedure, considering the early age of the patient.           Aim: To analyze the incidence and location of malignant and benign tumors in children up to 18 years of age over a period of 10 years.           Materials and methods: We conducted a retrospective study of 29 eyes from a cohort of 450 eyes with tumors operated on in our clinic between 2010 and 2019. Of all tumors of the eye and adnexa, only tumors of the eyelids were considered. All tumors were histopathologically examined after their surgical removal.           Results: Eyelid tumors in children account for 6.4% of the tumors studied in all age groups, and 0.2% of them are malignant. The ratio of women to men is 62% to 38%, with most of them residing in cities. The most common eyelid tumors in children are cysts (47%), followed by papillomas (17%) and nevi (10%). The distribution on the eyelid is as follows: medially located 31%, centrally 45% and temporally 24%.           Conclusion: Eyelid tumors in children prefer the female sex. Malignant tumors of the eyelids are rare. The average size of tumors is about 4-6 mm. The duration of the disease directly correlates with the size of the tumor. For tumors of the lower eyelid, a doctor is consulted earlier than for tumors of the upper eyelid. Inflammatory reaction around the tumor is more common in the right eye.</p>
					<p><a href="https://foliamedica.bg/article/123678/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/123678/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/123678/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Sat, 31 Aug 2024 14:50:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Acinar cell pancreatic carcinoma: a rare case of pancreatic tumor and short review of literature</title>
		    <link>https://foliamedica.bg/article/114880/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(3): 441-444</p>
					<p>DOI: 10.3897/folmed.66.e114880</p>
					<p>Authors: Spiros Delis, Dimosthenis Chrysikos, Dimitris Liatsos, Eugenia Charitaki, Ameer Shehade, Alexandros Samolis, Theodore Troupis</p>
					<p>Abstract: Pancreatic acinar cell carcinoma (PACC) is a rare subgenre of pancreatic adenocarcinoma, where the cells show acinar architecture. Specified causes of this neoplasia have not yet been deduced and it usually appears with nonspecific symptoms. Diagnosis is based on its characteristics in various imaging techniques, on its histological characteristics and the expression of specific immunohistochemical biomarkers. Surgical excision of the tumor is usually performed with high chances of recurrence, whereas the benefits of radiotherapy and chemotherapy are still ambiguous. In this paper, a 51-year-old female patient with a mass in the head of the pancreas was taken as a case study. She presented with icterus and imaging showed a defined mass in the head of the pancreas accompanied by dilation of the biliary tree. Biopsy and histological assessment done after the surgical excision showed components of PACC differentiation. The patient was regulated after surgery, especially regarding endocrinology and immunology.</p>
					<p><a href="https://foliamedica.bg/article/114880/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/114880/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/114880/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Sun, 30 Jun 2024 15:35:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Poland’s syndrome and breast cancer: coincidence or not?</title>
		    <link>https://foliamedica.bg/article/113837/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(3): 436-440</p>
					<p>DOI: 10.3897/folmed.66.e113837</p>
					<p>Authors: Anna Bumbu, Serghei Covantsev, Anna Sukhotko, Dmitry Grekov, Daria Turovets</p>
					<p>Abstract: Poland’s syndrome is an uncommon congenital anomaly of unknown etiology, the main characteristic of which is the absence of the major pectoral muscle. Thorax and upper limb malformations also may be present. Poland’s syndrome has been observed in clinical cases connected to a variety of neoplasia, primarily hematological disorders. Patients with Poland’s syndrome who have developed breast cancer have been reported incidentally. Here we report a case of Poland’s syndrome associated with breast cancer.</p>
					<p><a href="https://foliamedica.bg/article/113837/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/113837/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/113837/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Sun, 30 Jun 2024 15:35:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>A nine-year-old child with nasopharyngeal cancer treated with concomitant chemoradiotherapy with cisplatin – a case report</title>
		    <link>https://foliamedica.bg/article/122593/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(3): 421-425</p>
					<p>DOI: 10.3897/folmed.66.e122593</p>
					<p>Authors: Veselin Popov, Gulhan Suleyman, Neofit Spasov, Stefan Pavlov, Gabriela Raycheva</p>
					<p>Abstract: In recent years, the role of radiation oncology in treating various pediatric cancers has been extensively researched and developed. The dosage of radiotherapy, when combined with chemotherapy, was either reduced in some oncological diseases or modified in other cancers. Despite these changes, due to swift advancements in radiation oncology technology, this combination therapy continues to enhance both overall and progression-free survival rates, maintaining its vital status as a therapeutic approach in precision medicine.     We report here a nine-year-old patient with nasopharyngeal carcinoma treated according to SIOPE guidelines, which included induction neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with cisplatin. Post-therapy imaging assessments revealed a persistent tumor mass with reduced dimensions on MRI one month after treatment, characterized by absence of contrast enhancement, water diffusion restriction, or lymphadenopathy. Subsequent CT imaging at three months post-radiotherapy showed no signs of disease progression. Repeat MRI scans at four and six months post-treatment demonstrated stable disease without evidence of water diffusion restriction, indicating a positive response to therapy. These results underscore the effectiveness of the multimodal approach in achieving favorable tumor control and therapeutic efficacy in pediatric nasopharyngeal carcinoma.</p>
					<p><a href="https://foliamedica.bg/article/122593/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/122593/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/122593/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Sun, 30 Jun 2024 15:35:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Expression of ten-eleven translocation 2 and glutathione-S-transferase pi in colorectal cancer patients with and without type 2 diabetes mellitus</title>
		    <link>https://foliamedica.bg/article/122713/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(3): 370-379</p>
					<p>DOI: 10.3897/folmed.66.e122713</p>
					<p>Authors: Stamatis S. Papadatos, Antigoni Mitselou, Evangeli Lampri, Christina Bali, Antonia Betzou, Anna Varouktsi, Konstantinos Katsanos, Vasiliki Galani</p>
					<p>Abstract: Aims: To highlight possible correlations of type 2 diabetes mellitus (T2DM) with microscopic / macroscopic characteristics of colorectal cancer tissues, along with the expression of Ten-Eleven Translocation 2 (TET2) and glutathione-S-transferase pi (GST-pi) proteins.           Materials and methods: Tumors from 46 patients were embedded in paraffin blocks, stained with hematoxylin-eosin and studied microscopically. Immunohistochemical study of TET2 and GST-pi expression was performed. The results were analyzed and correlated with T2DM as comorbidity.           Results: All tumors expressed GST-pi at three levels (weak, moderate, and strong); two out of three tumors showed either weak or moderate TET2 expression. Patients without T2DM tended to have tumors with weak or no expression of TET2 (p=0.038) whereas diabetic patients’ tumors showed a significantly higher percentage of strong or moderate GST-pi expression (p=0.034). On binomial logistic regression, tumors excised from T2DM patients were 6.9 times more likely to show moderate (rather than weak and none) TET2 expression compared to tumors from non-diabetic patients (95% CI [1.33, 35.75]), and a 2.7-fold higher relative likelihood of showing strong (rather than moderate and weak) GST-pi expression (95% CI [0.63, 12.09]), taking into account sex, age, and tumor size. The association between T2DM and TET2 expression remains statistically significant in additional binomial analysis that was performed taking into account certain histological tumor characteristics.           Conclusions: TET2 and GST-pi are expressed in malignant colon tumors. T2DM in CRC patients was associated with the highest observed GST-pi expression; absence of T2DM was associated with the lowest observed TET2 expression. T2DM increases the probability of observing GST-pi and TET2 expression at maximum levels, independent of specific tumor microscopic features and certain patient characteristics.</p>
					<p><a href="https://foliamedica.bg/article/122713/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/122713/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/122713/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Sun, 30 Jun 2024 15:34:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>The expanding role of artificial intelligence in the histopathological diagnosis in urological oncology: a literature review</title>
		    <link>https://foliamedica.bg/article/124998/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(3): 303-311</p>
					<p>DOI: 10.3897/folmed.66.e124998</p>
					<p>Authors: Jasmin Gurung, Mladen Doykov, Gancho Kostov, Bozhidar Hristov, Peter Uchikov, Krasimir Kraev, Daniel Doykov, Katya Doykova, Siyana Valova, Emiliya Nacheva-Georgieva, Eduard Tilkiyan</p>
					<p>Abstract: The ongoing growth of artificial intelligence (AI) involves virtually every aspect of oncologic care in medicine. Although AI is in its infancy, it has shown great promise in the diagnosis of oncologic urological conditions. This paper aims to explore the expanding role of artificial intelligence in the histopathological diagnosis in urological oncology. We conducted a focused review of the literature on AI in urological oncology, searching PubMed and Google Scholar for recent advancements in histopathological diagnosis using AI. Various keyword combinations were used to find relevant sources published before April 2nd, 2024. We approached this article by focusing on the impact of AI on common urological malignancies by incorporating the use of different AI algorithms. We targeted the capabilities of AI’s potential in aiding urologists and pathologists in histological cancer diagnosis. Promising results suggest AI can enhance diagnosis and personalized patient care, yet further refinements are needed before widespread hospital adoption. AI is transforming urological oncology by improving histopathological diagnosis and patient care. This review highlights AI’s advancements in diagnosing prostate, renal cell, and bladder cancer. It is anticipated that as AI becomes more integrated into clinical practice, it will have a greater influence on diagnosis and improve patient outcomes.</p>
					<p><a href="https://foliamedica.bg/article/124998/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/124998/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/124998/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Invited Review</category>
		    <pubDate>Sun, 30 Jun 2024 15:10:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>A rare clinical case of extra-gastrointestinal stromal pancreatic tumor</title>
		    <link>https://foliamedica.bg/article/113215/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(2): 291-297</p>
					<p>DOI: 10.3897/folmed.66.e113215</p>
					<p>Authors: Alexey Shabunin, Zurab Bagatelia, Mikhail Tavobilov, David Dolidze, Igor Andreytsev, Tatiana Sheviakova, Nataliya Ivanova, Anna Foshina, Zarui Chibukhchyan, Serghei Covantsev</p>
					<p>Abstract: Extra-gastrointestinal stromal tumors arising from the pancreas are extremely rare. To date, just over 30 cases have been described in the world literature. A clinical observation of a 67-year-old patient with dull epigastric pain and a large cystic solid neoplasm instrumentally identified as an extra-gastrointestinal stromal tumor of the head of the pancreas is presented. The volume of surgical intervention consisted of pancreatogastroduodenectomy and right-sided hemicolectomy, since tumor invasion into the transverse mesocolon was detected intraoperatively. The final diagnosis of extra-gastrointestinal stromal sarcoma of the head of the pancreas with invasion into the mesocolon pT4N0M0, stage IIIb was made on the basis of histopathology and immunohistochemistry results.     Extra-gastrointestinal stromal pancreatic tumors require careful differential diagnosis with other large abdominal masses. Timely diagnosis and use of modern treatment algorithms make it possible to avoid further disease progression.</p>
					<p><a href="https://foliamedica.bg/article/113215/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/113215/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/113215/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Tue, 30 Apr 2024 20:00:20 +0000</pubDate>
		</item>
	
		<item>
		    <title>Can FDG-PET assess the response to chemotherapy and predict tissue necrosis in osteosarcoma and Ewing sarcoma?</title>
		    <link>https://foliamedica.bg/article/117148/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(2): 196-202</p>
					<p>DOI: 10.3897/folmed.66.e117148</p>
					<p>Authors: Lorenzo Andreani, Edoardo Ipponi, Alfio Damiano Ruinato, Tommaso Lupi, Federico Di Sacco, Duccio Volterrani, Luca Coccoli, Rodolfo Capanna</p>
					<p>Abstract: Introduction: Osteosarcoma (OS) and Ewing sarcoma (ES) represent the pediatric population’s most common malignant bone tumors. 18-Fluorodeoxyglucose positron emission tomography has been shown to be effective in both the diagnostic and staging phases of cancer treatment. In recent years, some studies have also explored the possibility that FDG-PET could have a prognostic role.           Aim: Our research aimed to evaluate if maximum standardized uptake value (SUVmax) variations after chemotherapy could be correlated with tissue necrosis and be linked with patients’ survival rates.           Materials and methods: This observational retrospective study included all cases treated for skeletal OS or ES in our institution between 2006 and 2018. We recorded patients’ SUVmax values before and after chemotherapy, the necrosis grade (for those who received surgery), and survivorship. Forty-one cases (17 OS and 24 ES) were included. Among the 36 cases that received surgery, 15 were responders, and 20 were non-responders.           Results: Our data suggested a statistically significant correlation between tumor necrosis and differential SUVmax after neoadjuvant treatment (p=0.007). In particular, cases with differential SUVmax higher than 4.7 or a variation higher than 63% had better oncological outcomes.           Conclusion: Our study testifies to the effectiveness of FDG-PET in predicting tissue necrosis on ES and OS, thereby representing a promising prognostic factor.</p>
					<p><a href="https://foliamedica.bg/article/117148/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/117148/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/117148/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Tue, 30 Apr 2024 20:00:06 +0000</pubDate>
		</item>
	
		<item>
		    <title>Paraovarian tumor of borderline malignancy: A case report</title>
		    <link>https://foliamedica.bg/article/116865/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(1): 128-131</p>
					<p>DOI: 10.3897/folmed.66.e116865</p>
					<p>Authors: Dimitrios Bairaktaris, Stefania Tsoplaktsoglou, Efthymia Souka, Konstantinos Kalmantis, Christos Iavazzo</p>
					<p>Abstract: Paraovarian tumors of borderline malignancy (PTBM) are exceedingly rare, with only slightly over 60 cases reported worldwide. This report presents the case of a 22-year-old nulliparous patient who incidentally discovered a left paraovarian mass during a routine abdominal ultrasound. Subsequent MRI revealed a 2.5×2.1 cm cystic lesion located in close proximity to, but outside of, the left ovary, with no other pathological findings. A laparoscopic cystectomy was performed with meticulous care to prevent tumor spillage, and the patient experienced an uneventful recovery. Histopathological examination unveiled irregularly shaped tissue measuring 2.2×1.2×1 cm, characterized by fibrous tissue/wall with spindle cell stroma and an epithelium displaying features consistent with a serous borderline tumor. Our multidisciplinary team recommended diligent follow-up. This case contributes to the existing literature on PTBM and highlights the imperative for additional cases to enhance our comprehension of the optimal management of these exceedingly rare tumors.</p>
					<p><a href="https://foliamedica.bg/article/116865/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/116865/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/116865/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Thu, 29 Feb 2024 22:00:17 +0000</pubDate>
		</item>
	
		<item>
		    <title>Complications after limb salvage surgeries for musculoskeletal malignancies: 10-year experience of the main sarcoma center in Bulgaria</title>
		    <link>https://foliamedica.bg/article/113390/</link>
		    <description><![CDATA[
					<p>Folia Medica 66(1): 35-40</p>
					<p>DOI: 10.3897/folmed.66.e113390</p>
					<p>Authors: Yordan St. Ivanov, Kircho Patrikov</p>
					<p>Abstract: Introduction: Limb salvage surgery is currently the most frequently used treatment option in Bulgaria for individuals with musculoskeletal malignancies. Clinical data about complications from these procedures is limited in the country, with only a few studies currently available.           Aim: The aim of our study is to analyze complication rates and patterns in Bulgarian patients treated with limb salvage surgery for musculoskeletal malignancies.           Materials and methods: Our series consist of a retrospective review of 43 patients with musculoskeletal malignancies, who underwent limb salvage surgeries at Boycho Boychev University Orthopedic Hospital in Sofia, Bulgaria, over a period of 10 years. For staging, we used the AJCC and Enneking’s staging systems for malignant musculoskeletal tumors. Functionality was assessed with the MSTS system. Assessment of complications was done with a modified Clavien-Dindo classification for surgical complications and Henderson’s classification of failure of limb salvage after reconstructive surgery.           Results: The mean follow-up time for the series is 40 months (range 12 to 120 months). At the current follow-up, the overall survival rate for the series is 72%. The overall complication rate for the series is 72% and the surgical revision rate is 46.5%. Of the encountered complications, 84% were classified as grade Ⅲb using the Clavien-Dindo classification.           Conclusion: Bulgarian patients treated with limb salvage for musculoskeletal malignancies have high complication rates, with no clear prevalence between mechanical and non-mechanical complication patterns. Many of the encountered complications are severe and require additional surgical management.</p>
					<p><a href="https://foliamedica.bg/article/113390/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/113390/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/113390/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Thu, 29 Feb 2024 22:00:05 +0000</pubDate>
		</item>
	
		<item>
		    <title>Uterine tumor resembling ovarian sex-cord tumor – a rare gynecological neoplasm</title>
		    <link>https://foliamedica.bg/article/100064/</link>
		    <description><![CDATA[
					<p>Folia Medica 65(6): 1020-1024</p>
					<p>DOI: 10.3897/folmed.65.e100064</p>
					<p>Authors: Georgi D. Prandzhev, Tihomir P. Totev, Svetlana A. Mateva, George Mathew, Grigor A. Gortchev</p>
					<p>Abstract: Uterine tumor resembling ovarian sex-cord tumor is a rare group of uterine neoplasms with unknown histogenesis and differentiation towards ovarian sex-cord elements. They are benign in nature with low malignancy potential. Diagnosis is based on immunohistochemistry and morphological features, and the distinction from other more malignant differentials is paramount to correctly individualizing treatment.        A 47-year-old patient was admitted to the hospital complaining of abdominal pain and abnormal uterine bleeding. Subsequent detection of multiple uterine fibroids by ultrasound study and CT scans lead to a robot-assisted total hysterectomy. Histological studies revealed that one of the fibroids in the myometrium had a morphology resembling an ovarian sex-cord tumor with low Ki-67 proliferative activity. After 12 months of follow-up, no additional treatment was required, and no signs of recurrence or progression were observed.        Uterine tumor resembling ovarian sex-cord tumor is a rare gynecological entity with no established treatment protocol. Differentiation between benign and malignant behavior is based on structural features and immunohistochemical expression assessment. This highlights the importance of immunohistochemical staining and morphological analysis to determine the degree of surgical radicality. ﻿Minimally invasive approach is feasible and safe, but more experience is needed for further conclusions.</p>
					<p><a href="https://foliamedica.bg/article/100064/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/100064/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/100064/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Sun, 31 Dec 2023 19:00:23 +0000</pubDate>
		</item>
	
		<item>
		    <title>Laparoscopic para-aortic lymphadenectomy for metastatic colon cancer in a patient with left-sided inferior vena cava: a case report</title>
		    <link>https://foliamedica.bg/article/96691/</link>
		    <description><![CDATA[
					<p>Folia Medica 65(6): 1015-1019</p>
					<p>DOI: 10.3897/folmed.65.e96691</p>
					<p>Authors: Efstathios Kotidis, Elissavet Anestiadou, Aikaterini Karamitsou, Georgios Gemousakakis, Orestis Ioannidis, Stefanos Bitsianis, Savvas Symeonidis, Nikolaos Ouzounidis, Odysseas Lomvardeas, Stamatios Aggelopoulos</p>
					<p>Abstract: Transposition of inferior vena cava, or, left-sided inferior vena cava (LS-IVC) is a rare clinical entity, in which the inferior vena cava ascends along the left side of the abdominal aorta. Literature contains mainly clinical case reports. Although it is usually not associated with clinical symptomatology, this anomaly should be detected during preoperative planning to avoid iatrogenic injuries intraoperatively. We present a case of left-sided inferior vena cava encountered during laparoscopic lymphadenectomy in a 45-year-old man with previous laparoscopic hemicolectomy due to colon adenocarcinoma. Preoperative CT abdomen revealed the left-sided location of infrarenal IVC and laparoscopic trans-peritoneal aortic lymphadenectomy was decided. Intraoperatively, transposition of inferior vena cava was confirmed in accordance with the CT findings. Resection of lymph node block was conducted with no complications and with minimal blood loss. The postoperative course was uneventful, and the patient was discharged from the hospital the day following surgery. In conclusion, transposition of the inferior vena cava, although rare, constitutes an anatomical variant that should be identified preoperatively to decrease intraoperative risks. Several anatomical variants have been associated with left-sided inferior vena cava.</p>
					<p><a href="https://foliamedica.bg/article/96691/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/96691/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/96691/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Sun, 31 Dec 2023 19:00:22 +0000</pubDate>
		</item>
	
		<item>
		    <title>Asynchronous bilateral male breast cancer. A rare case report</title>
		    <link>https://foliamedica.bg/article/96190/</link>
		    <description><![CDATA[
					<p>Folia Medica 65(6): 1011-1014</p>
					<p>DOI: 10.3897/folmed.65.e96190</p>
					<p>Authors: Teodor Aleksiev, Zlatina Ivanova, Hristo Dobrev</p>
					<p>Abstract: We describe a rare case of asynchronous bilateral carcinoma of the mammary glands in a 66-year-old man. The patient was admitted to the Department of Dermatology and Venereology due to exacerbation of chronic eczema. During the examination, a 3×2-cm tumor with retraction of the mammilla was found in the right mammary gland. Mastectomy and regional lymphatic dissection were performed. Histological examination showed invasive ductal carcinoma, ER (+) 70%, PR (−), HER2 (−). Treatment included chemotherapy, radiotherapy, and hormone therapy. Three years later, the patient reported a lump in the left breast. The presence of a tumor formation was confirmed by mammography and ultrasound examination. A radical mastectomy with regional lymphatic dissection was performed. Histological examination showed invasive ductal carcinoma of the mammary gland, ER (3+) 80%, PP (2+) 60%, HER2 (+++), and Ki67 (+) 80%. Treatment with chemotherapy and radiation therapy was carried out. Five years after diagnosis of the second carcinoma, the patient is in a good general condition. Regardless of its rarity, the described case should draw doctors’ attention to this pathology. Assessment of risk factors and periodic breast examination in men would allow early diagnosis, timely treatment, and better prognosis of the disease.</p>
					<p><a href="https://foliamedica.bg/article/96190/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/96190/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/96190/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Sun, 31 Dec 2023 19:00:21 +0000</pubDate>
		</item>
	
		<item>
		    <title>Triple synchronous malignancies of the stomach, bladder and thyroid in a previously treated prostate cancer patient: A Case Report</title>
		    <link>https://foliamedica.bg/article/96012/</link>
		    <description><![CDATA[
					<p>Folia Medica 65(4): 693-698</p>
					<p>DOI: 10.3897/folmed.65.e96012</p>
					<p>Authors: Oliver Oey, Siaw Sze Tiong, Sze Ling Wong, Suresh Navadgi, Yasir Khan</p>
					<p>Abstract: Cancers that develop within six months of the first primary cancer are referred to as synchronous malignancies. These malignancies are difficult to diagnose and treat, with treatment primarily based on case reports.        We report here the case of a 51-year-old male with prior history of prostate cancer who presented with haematuria to the general practice. A CT pyelogram showed left bladder wall lesion that was further investigated with cystoscopy and biopsy confirmed as muscle-invasive urothelial carcinoma. Incidentally, two perigastric nodes and hepatic lesions were noted on CT. FDG-PET revealed high-grade uptake in the right lobe of thyroid gland and cervical nodes that was biopsy proven as papillary thyroid carcinoma. Subsequently, gastroscopy and a biopsy of the gastric lesion confirmed a gastric neuroendocrine tumour. The patient underwent chemoradiotherapy, total thyroidectomy, and commenced somatostatin analogue for treatment of urothelial carcinoma, papillary thyroid carcinoma, and neuroendocrine tumour, respectively.        The diagnosis and treatment of synchronous malignancies is complex. A multidisciplinary team approach is required to improve treatment outcomes.</p>
					<p><a href="https://foliamedica.bg/article/96012/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/96012/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/96012/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Thu, 31 Aug 2023 14:00:23 +0000</pubDate>
		</item>
	
		<item>
		    <title>Fibrosarcoma with deceptive benign presentations: a report of two cases</title>
		    <link>https://foliamedica.bg/article/91065/</link>
		    <description><![CDATA[
					<p>Folia Medica 65(4): 686-692</p>
					<p>DOI: 10.3897/folmed.65.e91065</p>
					<p>Authors: Daphne J. Theodorou, Stavroula J. Theodorou, Yousuke Kakitsubata</p>
					<p>Abstract: Low-grade fibromyxoid sarcoma and myxofibrosarcoma are malignant soft tissue tumors, fibrosarcomas, of shared clinical and imaging appearances. We report sarcomatous lesions in soft tissue with deceptively benign clinical and imaging appearances, and correlate findings with those of histologic analysis. Two patients presented with a long history of painless swelling at the dorsum and upper extremity and denied any constitutional symptoms. Sonography and magnetic resonance imaging suggested the presence of benign soft tissue lesions of a predominant fluid-like consistency. Despite indolent clinical and imaging characteristics, in both cases, histopathology disclosed a diagnosis of spindle cell-type soft tissue sarcoma, designating an aggressive tumor. Knowledge of the seemingly benign clinical and imaging features of fibrosarcomas is required to raise the possibility of malignancy in soft tissue that may be underdiagnosed or misdiagnosed. The importance of a correct diagnosis and the implications of surgical resection, irradiation, and systemic oncological therapy are quite obvious.</p>
					<p><a href="https://foliamedica.bg/article/91065/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/91065/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/91065/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Thu, 31 Aug 2023 14:00:21 +0000</pubDate>
		</item>
	
		<item>
		    <title>A metachronous second primary lung cancer after laryngectomy for laryngeal carcinoma</title>
		    <link>https://foliamedica.bg/article/85074/</link>
		    <description><![CDATA[
					<p>Folia Medica 65(4): 671-674</p>
					<p>DOI: 10.3897/folmed.65.e85074</p>
					<p>Authors: Georgi Yankov, Magdalena Alexieva, Stefka Yankova, Evgeni Mekov</p>
					<p>Abstract: A combination of laryngeal carcinoma and subsequent primary lung cancer is rare yet important in terms of therapeutic strategy and prognosis.        We present a case of primary squamous cell laryngeal carcinoma treated with laryngectomy and chemoradiation therapy. One year later, the patient developed metachronous squamous cell carcinoma of the lung and underwent left pneumonectomy.        A second primary lung cancer after laryngeal cancer presents a significant challenge for surgeons, oncologists, and radiotherapists. The differentiation between lung metastasis and primary lung cancer is of paramount importance for the correct therapeutic strategy and prognosis.</p>
					<p><a href="https://foliamedica.bg/article/85074/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/85074/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/85074/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Thu, 31 Aug 2023 14:00:19 +0000</pubDate>
		</item>
	
		<item>
		    <title>First case of medullary osteogenic sarcoma of the pelvis: 12-year follow-up of reconstruction with hemipelvis allograft after resection</title>
		    <link>https://foliamedica.bg/article/76144/</link>
		    <description><![CDATA[
					<p>Folia Medica 65(3): 508-513</p>
					<p>DOI: 10.3897/folmed.65.e76144</p>
					<p>Authors: Recep Öztürk, Ahmet Fevzi Kekeç, Bedii Şafak Güngör</p>
					<p>Abstract: A 45-year-old male patient with low-grade central osteosarcoma (LGCO) in the periacetabular region underwent wide resection, fresh frozen hemipelvis allograft reconstruction, and total hip prosthesis. To the best of our knowledge, this case is the first example of low-grade osteogenic sarcoma in flat bones. Aseptic loosening of the acetabular cup was observed 44 months after the operation, and it was revised with a constrained acetabular cup. Recurrent subluxation due to constraint ring failure and cup malposition was observed at 89 months after the revision surgery. Revision operation was performed with cage + non-constrained cup. Twelve years after the first operation, he is in exceptionally functional and disease-free condition. He can walk unlimited distances without pain. Radiographs show complete union at the junction of the allograft and disease-free bone.        In conclusion, fresh frozen hemipelvis allograft is one of the best reconstructive options following hemipelvectomy because of its potential durability and capacity to restore pelvic stability and preserve functionality.</p>
					<p><a href="https://foliamedica.bg/article/76144/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/76144/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/76144/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Fri, 30 Jun 2023 20:00:22 +0000</pubDate>
		</item>
	
		<item>
		    <title>Expression of Snail and Twist compared with clinical and pathological parameters in patients with gastric cancer</title>
		    <link>https://foliamedica.bg/article/84132/</link>
		    <description><![CDATA[
					<p>Folia Medica 65(3): 393-398</p>
					<p>DOI: 10.3897/folmed.65.e84132</p>
					<p>Authors: Elena Poryazova, Denitsa Serteva, Daniel Markov, Veselin Chonov, Galabin Markov</p>
					<p>Abstract: Introduction: Epithelial-mesenchymal transition (EMT) is a process of change in the cellular phenotype from epithelial to mesenchymal morphology. The changes at the cellular level can explain the great heterogeneity and plasticity in the different histological subtypes of gastric carcinomas, which causes difficulties in therapy. In it, epithelial cells reduce intercellular adhesion, which is crucial in the process of invasion and metastasis of gastric carcinomas. Inhibition of cell adhesion molecules such as E-cadherin is known to be influenced by a number of transcription factors, such as Snail and Twist.                  Materials and methods: Our study aims to examine immunohistochemically the expression of the transcription factors Snail and Twist in 69 patients with gastric cancer and to look for a link between their expression and clinical and pathological characteristics.                  Results: Positive expression of Snail and Twist was observed in all cases studied by us. We observed heterogeneity and different intensity of immunohistochemical expression. There is a correlation between the immunohistochemical expression and the degree of differentiation of tumor cells and the tumor stage. The cells of poorly differentiated adenocarcinomas show diffuse and strong nuclear staining. No correlation was found between the expression of the two markers, age, and sex of the patients.                  Conclusions: Evaluating the expression of the two markers studied may help to assess tumor progression and prognosis. They can be used for more accurate and effective diagnosis in precancerous lesions and in early gastric cancer because they are not expressed in the normal gastric mucosa.</p>
					<p><a href="https://foliamedica.bg/article/84132/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/84132/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/84132/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Fri, 30 Jun 2023 20:00:06 +0000</pubDate>
		</item>
	
		<item>
		    <title>Giant inflammatory pseudotumor of the lung: a case report</title>
		    <link>https://foliamedica.bg/article/98342/</link>
		    <description><![CDATA[
					<p>Folia Medica 65(2): 316-320</p>
					<p>DOI: 10.3897/folmed.65.e98342</p>
					<p>Authors: Alexey Shabunin, Dmitry Grekov, Viktor Yakomaskin, Alexander Kuzmenko, Serghei Covantsev</p>
					<p>Abstract: The inflammatory myofibroblastic tumor, which was first described in 1939, is a rare neoplasm that accounts for 0.04%–0.7% of all lung neoplasms. These neoplasms occur most often in children, as they are the most common primary lung tumors in children. Preoperative diagnosis of such patients using bronchoscopy with endoluminal biopsy and transthoracic biopsy is not always informative and often the diagnosis can only be established during surgery. The presented case shows that on rare occasions, a giant myofibroblastic tumor of the lung may be encountered in adults, and radical intervention with subsequent rehabilitation can lead to full recovery.</p>
					<p><a href="https://foliamedica.bg/article/98342/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/98342/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/98342/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Sun, 30 Apr 2023 17:49:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Giant cell tumor of the patellar tendon sheath in childhood: case report</title>
		    <link>https://foliamedica.bg/article/68256/</link>
		    <description><![CDATA[
					<p>Folia Medica 65(2): 301-304</p>
					<p>DOI: 10.3897/folmed.65.e68256</p>
					<p>Authors: Konstantinos Skarentzos, Dimitra Panteli, Reichan Molla Moustafa, Stylianos Tottas, Ioannis E. Kougioumtzis, Georgios I. Drosos</p>
					<p>Abstract: ﻿The aim of this study was to report a rare case of a giant cell tumor of the patellar tendon sheath. This indicates the diagnostic procedures and treatment options for giant cell tumors of the patellar tendon. This study reported a case of a 13-year-old male patient with a giant cell tumor of the tendon sheath. In our case, open arthrotomy was performed with complete surgical excision of the lesion. Histopathological examination revealed a giant cell tumor. At the last follow-up, 2 years after surgery, no complications were reported. The giant cell tumor of the patellar tendon sheath is an uncommon benign tumor. It mimics common knee symptoms. A differential diagnosis is definitely a challenge. Available operation approaches have demonstrated similar results, which lead to symptom relief and a low recurrence rate.</p>
					<p><a href="https://foliamedica.bg/article/68256/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/68256/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/68256/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Sun, 30 Apr 2023 17:41:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Functional results after reconstruction with modular tumor endoprostheses in patients with malignant bone tumors</title>
		    <link>https://foliamedica.bg/article/75380/</link>
		    <description><![CDATA[
					<p>Folia Medica 65(1): 80-86</p>
					<p>DOI: 10.3897/folmed.65.e75380</p>
					<p>Authors: Yordan S. Ivanov, Tsvetan Tsenkov</p>
					<p>Abstract: Introduction: The functional outcome in patients after limb salvage surgery, and in particular reconstructions with modular tumor endoprostheses, has been the subject of many international series, but only a few publications mention the functionality in a Bulgarian patient group.                  Aim: The aim of the present study was to analyze the functional outcome in a Bulgarian group of patients with malignant bone tumors that underwent resection and reconstruction with modular tumor endoprostheses.                  Materials and methods: Our series consists of 14 patients with malignant bone tumors who underwent limb salvage surgery and reconstruction with modular tumor endoprostheses between February 2012 and January 2021. Staging was done using the AJCC staging system for bone sarcoma. The MSTS score system was used to evaluate the functional results.                  Results: The mean follow-up time was 38.5 months (range, 8 to 96). The mean MSTS score for our series was 70%. Distant metastases were found in 4 (28%) patients. Local recurrence occurred in 3 (21%) patients. The most severe late complication was a mechanical failure of the expanding mechanism in 1 patient.                  Conclusions: Reconstruction with modular tumor endoprostheses offer superb functionality and improved life quality in patients with primary malignant bone tumors.</p>
					<p><a href="https://foliamedica.bg/article/75380/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/75380/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/75380/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Tue, 28 Feb 2023 20:00:11 +0000</pubDate>
		</item>
	
		<item>
		    <title>Endobronchial localization - arena of two tumors: a case report</title>
		    <link>https://foliamedica.bg/article/71252/</link>
		    <description><![CDATA[
					<p>Folia Medica 64(6): 1003-1006</p>
					<p>DOI: 10.3897/folmed.64.e71252</p>
					<p>Authors: Spasimir Shopov</p>
					<p>Abstract: The lung is a common arena for metastases of tumors with different localization, but endobronchial localization of metastases is very rare. The most common tumors with endobronchial localization of metastasis are renal, breast, and colorectal cancer. We report a man presenting with cough and hemoptysis. Endobronchial biopsy showed renal cell carcinoma and micro-invasive bronchogenic squamous cell carcinoma. Endobronchial metastases from renal cell carcinoma are rare. The squamous cell lung cancer is one of the most common cancers in men, but the combination of renal cell carcinoma and micro-invasive squamous cell carcinoma with endobronchial localization is a casuistic case.</p>
					<p><a href="https://foliamedica.bg/article/71252/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/71252/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/71252/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Sat, 31 Dec 2022 12:00:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Thrombotic incidents in patients with myelofibrosis suggest to be independent of JAK2 V617F mutational status</title>
		    <link>https://foliamedica.bg/article/72175/</link>
		    <description><![CDATA[
					<p>Folia Medica 64(4): 655-660</p>
					<p>DOI: 10.3897/folmed.64.e72175</p>
					<p>Authors: Dragomira Nikolova, Atanas Radinov</p>
					<p>Abstract: Introduction: Myelofibrosis (MF) belongs to a group of conditions known as Philadelphia-negative myeloproliferative neoplasms (MPN). Bleeding or various vascular complications could be the main causes of morbidity and mortality in patients with MF. MPN- related thrombosis is a multifactorial process and in the case of myelofibrosis, little is known. The risk factors for thrombotic complications in MF have been rarely assessed.                  Aim: The purpose of this study was to investigate the incidence of thrombotic events in MF and the role of JAK2 V617F mutation as a risk factor for thrombotic incidents in patients with MF.                  Materials and methods: In our study of 37 patients, 35% had thrombotic events in the past. All patients were admitted to the Clinic of Hematology, St Ivan Rilski University Hospital, Sofia, Bulgaria between 2016 and 2019 and diagnosed based on the WHO criteria of 2016.                  Results: The majority of patients (23, 62%) proved positive for JAK2 (Janus kinase) V617F mutation carrying one (16, 70%) or two (7, 30%) mutated alleles. Thirteen of the patients (35%) had a thrombotic event in the past and 9 of them (69%) were carriers of JAK2 V617F mutation. Fourteen patients of those without thrombotic history (24, 58%) were also carriers of JAK2 V617F mutation.                  Conclusions: As a whole, we did not find a statistically significant difference between JAK2 V617F mutation and the frequency of thrombotic events. Rendering an account to the possible life-threatening complications, treatment decisions should be undertaken upon possible antithrombotic prevention in MF.</p>
					<p><a href="https://foliamedica.bg/article/72175/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/72175/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/72175/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Wed, 31 Aug 2022 17:30:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Effects of gold nanoparticles on oxidative stress status in bladder cancer 5637 cells</title>
		    <link>https://foliamedica.bg/article/66784/</link>
		    <description><![CDATA[
					<p>Folia Medica 64(4): 641-648</p>
					<p>DOI: 10.3897/folmed.64.e66784</p>
					<p>Authors: Sajedeh Daei, Roghayeh Abbasalipourkabir, Korosh Khanaki, Fatemeh Bahreini, Nasrin Ziamajidi</p>
					<p>Abstract: Introduction: Nanomedicine has recently been known as an emerging research area with promising applications in cancer diagnosis and treatment. Aside from this, gold nanoparticles (AuNPs), as one of the important components of nanomedicine, have attracted considerable attention due to their special physicochemical properties and lower toxicity than other nanoparticles. Despite the impressive advantages of AuNPs, it has not been yet determined whether oxidative stress contributes to the toxicity of AuNPs on bladder cancer.                  Aim: The aim of this study was to address this issue by conducting experiments in order to investigate the effects of 20 nm AuNPs on human bladder cancer 5637 cells.                  Materials and methods: The viability of 5637 cells was evaluated upon 24 hour exposure to different concentrations of AuNPs (0-50 µg/ml) by 3-(4, 5-dimethylthiazol, 2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay. In order to evaluate oxidative stress status, total antioxidant capacity (TAC), total oxidant status (TOS), malondialdehyde (MDA) and also activities of antioxidant enzymes including glutathione peroxidase (GPx), catalase (CAT) and superoxide dismutase (SOD) were all determined by colorimetric assay kits.                  Results: The results from our experiment showed that the cytotoxicity caused by AuNPs was dose-dependent and the IC50 value was found to be 43.14 µg/ml after 24-hour exposure. Furthermore, MDA and TOS levels were significantly increased in treated cells compared to untreated cells (p&lt;0.05). In contrast, TAC level and the activities of SOD, GPx, CAT were significantly decreased in AuNPs-treated groups as compared with the untreated cells (p&lt;0.05).                  Conclusions: Overall, AuNPs decrease the cell viability and increase oxidative stress in bladder cancer 5637 cells.</p>
					<p><a href="https://foliamedica.bg/article/66784/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/66784/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/66784/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Wed, 31 Aug 2022 17:30:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Improving gene expression analysis efficacy from formalin-fixed paraffin embedded tissues</title>
		    <link>https://foliamedica.bg/article/63599/</link>
		    <description><![CDATA[
					<p>Folia Medica 64(4): 602-608</p>
					<p>DOI: 10.3897/folmed.64.e63599</p>
					<p>Authors: Pantelis Dimaras, Oskan Tasinov, Desislava Ivanova, Yoana Kiselova-Kaneva, Nadezhda Stefanova, Maria Tzaneva, Diana Ivanova</p>
					<p>Abstract: Introduction: Improving RNA isolation and cDNA synthesis techniques has emerged due to advancements in the knowledge of molecular basis of most diseases. This in turn increased the need of higher quantity and quality of the extracted genetic material to be used for a variety of diagnostic tests and experiments.                  Aim: The aim of the study was to compare three modified methods for RNA extraction from formalin-fixed paraffin embedded (FFPE) biopsied tissue and different cDNA synthesis strategies to facilitate study of gene expression.                  Materials and methods: Compared RNA extraction methods were: lysis buffer, phenol-based extraction, and combination of both with concomitant use of silica-based spin columns. RNA quantity and purity were estimated spectrophotometrically. Different priming strategies for cDNA synthesis were applied: oligo dT, combination of oligo dT and random hexamer, and gene specific primer. Two-step RT-qPCR of ribosomal protein L37A on preamplified and non-preamplified cDNA templates was performed.                  Results: The combination of lysis buffer with phenol based extraction gave higher RNA yield. By doing cDNA preamplification, the confidence of detection by qPCR was raised, and efficiency was improved. The preamplified template increased the sensitivity of analysis.                  Conclusions: Together, the combination of approaches improved substantially the reproducibility and validity of quantitative gene expression analyses from FFPE tissues.</p>
					<p><a href="https://foliamedica.bg/article/63599/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/63599/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/63599/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Wed, 31 Aug 2022 17:30:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>A concise review of inflammatory biomarkers targeted cancer therapy</title>
		    <link>https://foliamedica.bg/article/68365/</link>
		    <description><![CDATA[
					<p>Folia Medica 64(4): 572-580</p>
					<p>DOI: 10.3897/folmed.64.e68365</p>
					<p>Authors: Ashish Shah, Chhagan Patel</p>
					<p>Abstract: Inflammation is considered a general protective reaction of localized tissue against injury, irritation, or swelling. Inflammation may be acute, which is part of the defensive response; or chronic, which may lead to the development of various diseases including cancer. Several pro-inflammatory genes play important role in the various cellular processes like cell proliferation, angiogenesis, metastasis, and suppression of apoptosis. These pro-inflammatory genes include TNF-α, interleukins, chemokines, MMPs, cyclooxygenase, lipoxygenase, iNOS, Jak/STAT pathway, etc. All these genes are mainly regulated by the transcription factor NF-κB, which is found active in many types of neoplastic cells. Therefore, developing molecules that target pro-inflammatory genes or transcription factor is believed to be one of the good strategies for development of anti-cancer agents. Literature data suggest that many anti-inflammatory agents, including non-steroidal anti-inflammatory drugs, corticosteroids, statins, metformin, embelin, and some natural products, can interfere with the tumor microenvironment by inhibiting pro-inflammatory genes or transcription factors and increasing cell apoptosis. This review describes the link between inflammation and cancer, the role of pro-inflammatory genes and transcription factors in the development of tumor cells, and the use of anti-inflammatory agents in cancer.</p>
					<p><a href="https://foliamedica.bg/article/68365/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/68365/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/68365/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Invited Review</category>
		    <pubDate>Wed, 31 Aug 2022 17:30:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Risk factors for pediatric glioma</title>
		    <link>https://foliamedica.bg/article/64431/</link>
		    <description><![CDATA[
					<p>Folia Medica 64(4): 566-571</p>
					<p>DOI: 10.3897/folmed..e64431</p>
					<p>Authors: Georgios Sioutas, Alexandrina Nikova, Theodossios Birbilis</p>
					<p>Abstract: Brain tumours are a heterogenic group, a subtype of which is arising from glial cells. Pediatric low-grade gliomas are the most common primary CNS tumour group in childhood, representing 25% to over 30% of pediatric CNS tumours. Pediatric high-grade gliomas are relatively rare and have a poor prognosis. Epidemiological studies have reported various potential risk factors, such as demographics, ionizing and nonionizing radiation, allergic conditions, and infections, immunologic, parental, genetic, and developmental risk factors. These risk factors are relatively unclear and understudied; thus, this narrative review aims to summarize all studies connecting risk factors and pediatric gliomas.</p>
					<p><a href="https://foliamedica.bg/article/64431/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/64431/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/64431/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Invited Review</category>
		    <pubDate>Wed, 31 Aug 2022 17:30:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Anterior pelvic exenteration and synchronous bilateral nephroureterectomy for BK polyoma virus induced urothelial carcinoma of the bladder: A case report</title>
		    <link>https://foliamedica.bg/article/77713/</link>
		    <description><![CDATA[
					<p>Folia Medica 64(3): 521-526</p>
					<p>DOI: 10.3897/folmed.64.e77713</p>
					<p>Authors: Oliver Oey, Pravin Viswambaram, Andrew Moe, Nicole Swarbick, Dickon Hayne</p>
					<p>Abstract: BK polyoma virus (BKV) is a known risk factor for the development of urothelial carcinoma. There is currently limited data on the management of BKV-induced urothelial carcinoma (BUC) of the bladder, with available data limited to case reports. It remains debatable whether radical cystectomy (RC) with removal of the native urinary tract or RC alone is the most optimal management for BUC of the bladder. BKV-induced urothelial carcinoma is rare, and its management is challenging in immunocompromised patients such as that of post-transplant patients. This case report provides additional insight into a rare disease, the management of which still lacks established guidelines and remains debatable.        We present a unique case of BKV-induced muscle-invasive urothelial carcinoma of the bladder in an immunosuppressed renal transplant patient who underwent open radical cystectomy, anterior pelvic exenteration, bilateral native nephroureterectomy and ileal conduit formation to transplant kidney. The patient remains recurrence-free with preserved graft function 2 years since surgery.        An aggressive management approach which involves anterior pelvic exenteration with removal of the native urinary tract may be favoured in young patients with BUC of the bladder with minimal comorbidities. However, treatment should be individualised for each individual patient.</p>
					<p><a href="https://foliamedica.bg/article/77713/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/77713/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/77713/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Thu, 30 Jun 2022 20:00:20 +0000</pubDate>
		</item>
	
		<item>
		    <title>Assessment of the methylene blue mediated photodynamic therapy on BCL2 and BAX genes expression at mRNA level and apoptosis of head and neck squamous cell carcinoma cell line</title>
		    <link>https://foliamedica.bg/article/60825/</link>
		    <description><![CDATA[
					<p>Folia Medica 64(2): 221-228</p>
					<p>DOI: 10.3897/folmed.64.e60825</p>
					<p>Authors: Shadi Kahalian, Maryam Koopaie, Neda Hakimiha, Sajad Kolahdooz</p>
					<p>Abstract: Aim: This study aimed to assess the effect of photodynamic therapy (PDT) on apoptosis of head and neck squamous cell carcinoma (HNSCC) cells by flow cytometry and evaluating BAX and BCL2 genes expression.                  Materials and methods: In this in vitro study, human HNSCC cell line (HN5; NCBI. C196) was used and after cell culture, they were divided into four groups: controls (group C), cells irradiated by a diode laser with a wavelength of 660 nm, 150 mW power, and 45 J/cm2 energy density (group L), cells treated by methylene blue (group MB), and cells treated using PDT (group MB plus L). The RNA was then extracted and subjected to quantitative reverse transcription polymerase chain reaction (qRT-PCR) to assess BCL2 and BAX genes expression. Flow cytometry analysis was performed to assess apoptosis. Data were analysed using ANOVA.                  Results: PDT caused significant down-regulation of BCL2 (p&lt;0.001) and significant overexpression of BAX (p&lt;0.05) and PDT induced apoptosis HNSCC cell line. Changes in expression of these genes were not significant in other groups (p&gt;0.05).                  Conclusions: Considering the down-regulation of BCL2 and overexpression of BAX after PDT using a 660-nm diode laser and MB with 3.2 µg/mL concentration and flow cytometry results, it is suggested that this modality can be introduced for induction of apoptosis in the HNSCC cell line.</p>
					<p><a href="https://foliamedica.bg/article/60825/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/60825/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/60825/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Sat, 30 Apr 2022 13:06:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Immunohistochemical expression of CK20, CK7, and CDX2 in colorectal carcinoma in correlation with pathomorphological characteristics</title>
		    <link>https://foliamedica.bg/article/60950/</link>
		    <description><![CDATA[
					<p>Folia Medica 64(2): 214-220</p>
					<p>DOI: 10.3897/folmed.64.e60950</p>
					<p>Authors: Nevena Ilieva, Desislava Tashkova, Dmitrii Staykov, Denitsa Serteva, Yana Feodorova, Nikolay Mehterov, Angelina Mollova, Svitlana Bachurska</p>
					<p>Abstract: Introduction: Colorectal carcinoma is the third most common cancer worldwide. The usual immunophenotype of colorectal adenocarcinoma is CDX2 positive, CK20 positive, and CK7 negative. Aberrant expression is reported in a variety of colorectal carcinomas but its relation to morphological variables and survival data is still unclear.                  Aim: The aim of this study was to investigate the correlation between the aberrant immunostaining of colorectal carcinoma and different clinicopathological characteristics.                  Materials and methods: Immunohistochemical expression of CK20, CK7, and CDX2 was evaluated in 71 cases of colorectal carcinoma. Statistical analysis was performed to identify correlations between the morphological characteristics and the immunoprofile of colorectal carcinoma.                  Results: Positive cytoplasmic and/or membranous signal for CK20 was observed in 66.2% of colorectal carcinomas. CK7 positive immunostaining was seen in 7% of the cases. In terms of combined expression of CK20 and CK7, the proportion of immunoprofile CK20+/CK7− was the highest, accounting for 46 out of 71 colorectal carcinomas, followed by CK20−/CK7−, then CK20−/CK7+ and CK20+/CK7+. Concerning CDX2, the majority of colorectal carcinomas (87.3%) showed positive staining. Statistically significant correlation was established between CDX2 expression and histologic grade and depth of tumour invasion. Loss of CK20 positivity was associated with higher histologic grade. No association between CK7 expression and histopathologic features was established.                  Conclusions: The results support the heterogeneity of colorectal cancer. Over 35% of the cases in this study showed deviations from the expected immunoprofile. This should be taken into consideration when diagnosing colorectal carcinoma in metastatic regions.</p>
					<p><a href="https://foliamedica.bg/article/60950/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/60950/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/60950/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Sat, 30 Apr 2022 13:04:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>“Security dilemma”: active immunotherapy before versus after radiation therapy alone or chemo-radiotherapy for newly diagnosed glioblastoma</title>
		    <link>https://foliamedica.bg/article/62981/</link>
		    <description><![CDATA[
					<p>Folia Medica 64(2): 195-201</p>
					<p>DOI: 10.3897/folmed.64.e62981</p>
					<p>Authors: Alexandrina S. Nikova, Georgios Sioutas, Michael Karanikas, Theodossios Birbilis</p>
					<p>Abstract: Management of glioblastoma should be aggressive and personalised to increase the quality of life. Many new therapies, such as active immunotherapy, increase the overall survival, yet they result in complications which render the search for the optimal treatment stra-tegy challenging.        In order to answer whether the available treatment options should be administered in a specific row, we performed a literature search and meta-analysis. The results show that overall survival among the different treatment groups was equal, while the rates of complications were unequal. After surgery, when active immunotherapy was administered before radiation, radiation and chemotherapy, complication rates were lower.        For newly diagnosed glioblastoma in adults, applying active immunotherapy after total resection but before the other complementary treatment options is associated with lower complication rates.</p>
					<p><a href="https://foliamedica.bg/article/62981/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/62981/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/62981/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Invited Review</category>
		    <pubDate>Sat, 30 Apr 2022 12:47:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Treatment approach in malignant left-bowel obstruction using self-expandable metallic stent: a case series</title>
		    <link>https://foliamedica.bg/article/67124/</link>
		    <description><![CDATA[
					<p>Folia Medica 64(1): 143-147</p>
					<p>DOI: 10.3897/folmed.64.e67124</p>
					<p>Authors: Nikola B. Boyanov, Katina T. Shtereva, Sergey K. Sergeev, Katerina I. Madzharova, Nikolay A. Stoynov, Desislava D. Dimitrova-Yurukova</p>
					<p>Abstract: Endoscopic self-expandable metallic stent (SEMS) decompression in patients with bowel obstruction due to colon carcinoma has been practiced for over two decades now, both in potentially curable cases and metastatic cancer. Using this case series, we aim to review the literature on the subject and to present our initial experience with using this technique as a bridge to single stage surgery, thus minimizing colostomy creation.        We retrospectively reviewed seven cases of bowel obstruction due to left-sided colonic cancer, between March 2020 and March 2021. All patients received SEMS prior to being treated, 7 to 13 days later, using either laparoscopic surgical techniques or open surgery methods. All seven patients underwent single stage surgery, eliminating the need for placing a temporary or permanent stoma, therefore minimizing the hospital stay and increasing the quality of life of the individual.        We concluded that treatment with SEMSs for bowel obstruction in colorectal cancer was safe and well tolerated, resulting in primary anastomosis and restoration of the intestinal passage and low short-term morbidity.</p>
					<p><a href="https://foliamedica.bg/article/67124/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/67124/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/67124/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Mon, 28 Feb 2022 10:19:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Evaluation of cases with infantile hemangioma requiring treatment</title>
		    <link>https://foliamedica.bg/article/58616/</link>
		    <description><![CDATA[
					<p>Folia Medica 64(1): 67-74</p>
					<p>DOI: 10.3897/folmed.64.e58616</p>
					<p>Authors: Hüsnü Maraşli, Can Acipayam, Ufuk Utku Güllü, Serpil Dinçer, Emine Füheda Dalgiç, Seda Nida Karaküçük, Sadik Yurttutan</p>
					<p>Abstract: Aim: Infantile hemangiomas are the most common benign vascular tumours in infants. In this study, we aimed to evaluate the effectiveness of propranolol therapy in patients with infantile hemangioma.                  Materials and methods: This study included patients with infantile hemangiomas in the age range of 0 to 24 months who received propranolol therapy between September 2015 and 2019. Hemangioma activity score, ultrasonography imaging and photographic evaluations were performed before and at 6 months of treatment. Parental satisfaction with the results of treatment was recorded.                  Results: Our study included 85 patients with infantile hemangioma requiring treatment. Twenty patients were boys and 65 were girls. The mean age at starting treatment was 7.2±5.9 months (median: 5.0). While the average lesion area measured by ultrasonography before treatment was 209.7±207.5 mm2, it reduced to 105.1±145.7 mm2 (p&lt;0.001) after treatment. Similarly, while the mean hemangioma activity score was 3.8±0.9 before treatment, it decreased significantly to 1.3±0.8 after the treatment (p&lt;0.001). A noticeable improvement in photographic evaluation with the treatment was observed in infantile hemangiomas of the patients and 82% of the families were satisfied with the results of the treatment.                  Conclusions: The results of the study suggested that propranolol therapy used in the treatment of infantile hemangioma is an effective treatment option according to the photographic comparison, ultrasonography data, and hemangioma activity score evaluations.</p>
					<p><a href="https://foliamedica.bg/article/58616/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/58616/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/58616/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Mon, 28 Feb 2022 09:56:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Does biopsy before excision have contribution to clinical results in patients with schwannoma? A single-center prospective observational study</title>
		    <link>https://foliamedica.bg/article/59138/</link>
		    <description><![CDATA[
					<p>Folia Medica 64(1): 55-60</p>
					<p>DOI: 10.3897/folmed.64.e59138</p>
					<p>Authors: Recep Öztürk, Emin Kürşat Bulut, Bedii Şafak Güngör</p>
					<p>Abstract: Introduction: This study aimed to investigate whether tru-cut biopsy before excision contributes to clinical outcomes in patients diagnosed with limb schwannoma.                  Materials and methods: Tru-cut biopsy was performed before excision in patients diagnosed with schwannoma of the extremity in clinical and radiological evaluations. All patients underwent total excision with microsurgical methods. Demographic data, complications of tru-cut biopsy, treatments, and clinical results were analyzed.                  Results: Data for 17 patients (9 males and 8 females) were analyzed. The mean age was 49.8 years. No complications related to tru-cut biopsy were observed. The mean preoperative and postoperative VAS scores were 4.3 and 0.4, respectively. One patient developed postoperative neurological complications. No recurrence was observed in any patient.                  Conclusions: In schwannomas of the extremities, tru-cut biopsy before excision is an applicable and reliable option. The preoperative diagnosis is ascertained as schwannoma, and the outcomes of making the excision with microsurgical techniques are quite good.</p>
					<p><a href="https://foliamedica.bg/article/59138/">HTML</a></p>
					<p><a href="https://foliamedica.bg/article/59138/download/xml/">XML</a></p>
					<p><a href="https://foliamedica.bg/article/59138/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Mon, 28 Feb 2022 09:56:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Crohn’s Disease of the Vulva: a Case Report</title>
		    <link>https://foliamedica.bg/article/58002/</link>
		    <description><![CDATA[
					<p>Folia Medica 63(6): 990-993</p>
					<p>DOI: 10.3897/folmed.63.e58002</p>
					<p>Authors: Kalliopi Kokkali, Christos Iavazzo, Efthimia Souka, Sofia Lekka, Alexandros Fotiou, Eirini Geramani, Victoria Psomiadou, George Vorgias</p>
					<p>Abstract: Crohn&rsquo;s disease is a multi-systemic chronic inflammatory disease that can affect various organs besides the gastrointestinal tract such as joints, uvea, and the skin. Vulvar Crohn&rsquo;s disease is a rare entity occurring with vulvar lesions that show typical Crohn&rsquo;s disease granulomatous inflammation but are not contiguous with the gastrointestinal involvement. Vulvar Crohn&rsquo;s disease can be easily confused with other granulomatous diseases and awareness that such involvement may precede gastrointestinal symptoms must be raised. Few cases of vulvar Crohn&rsquo;s disease have been reported in the literature to date. Here, we report a case of a 43-year-old woman with a 6-month history of a vulvar lesion; the patient was diagnosed with Crohn&rsquo;s disease of the large bowel just over a year ago.</p>
					<p><a href="https://foliamedica.bg/article/58002/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/58002/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Fri, 31 Dec 2021 10:30:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Primary Bartholin Adenocarcinoma: a Rare Case and Radiotherapy as Definitive Treatment</title>
		    <link>https://foliamedica.bg/article/57633/</link>
		    <description><![CDATA[
					<p>Folia Medica 63(6): 985-989</p>
					<p>DOI: 10.3897/folmed.63.e57633</p>
					<p>Authors: Lokot Donna Lubis, Sarah Dina, Derissa Khairina Khaidirman</p>
					<p>Abstract: Primary vulvar adenocarcinoma is a very rare neoplasm, accounting for only 1% of all gynecologic malignancies. Most of the glandular carcinomas originated from the Bartholin&rsquo;s gland. Because of the rare incidence, the pathogenesis and radiotherapy response are not fully understood. A 47-year-old female from our hospital was diagnosed with primary Bartholin adenocarcinoma and received radiotherapy as definitive treatment. We evaluated the presence of high-risk and low-risk human papillomavirus (HPV) DNA to associate the role of HPV infection, and evaluated its molecular features by the expression of vimentin, p16, estrogen receptor, progesterone receptor, S-100, and Ki 67.</p>
					<p><a href="https://foliamedica.bg/article/57633/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/57633/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Fri, 31 Dec 2021 10:30:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Invasive Pulmonary Aspergillosis in Patients with Haematological Malignancies and Hematopoietic Stem Cell Transplantation: a Single-Center Study</title>
		    <link>https://foliamedica.bg/article/65248/</link>
		    <description><![CDATA[
					<p>Folia Medica 63(6): 941-947</p>
					<p>DOI: 10.3897/folmed.63.e65248</p>
					<p>Authors: Denis Niyazi, Temenuga Stoeva, Svilena Atanasova, Rumyana Markovska, Ilina Micheva</p>
					<p>Abstract: Aim: The aim of this study was to evaluate the clinical significance of Aspergillus Galactomannan antigen (GM) test for the diagnosis of invasive pulmonary aspergillosis (IPA) in patient with hematological malignancies, including patients undergoing hematopoietic stem cell transplantation (HSCT).Materials and methods: Between January 2016 and June 2019, ninety patients were tested for GM. A total of 134 blood and 19 bronchoalveolar lavage (BAL) samples were analyzed using Platelia Aspergillus Ag Enzyme-Immuno Assay (Bio-Rad Laboratories). The median age of patients was 63 years (range 25&ndash;81). Fifty-six patients (62.2%) were male. All patients were allocated into five groups on the basis of their GM results.Results: A positive GM antigen test was detected in 16 patients (17.7%). Of these, ten had positive serum samples (group I). After re-testing, 1 patient from group I gave a negative result. Five patients with negative serum samples gave positive BAL results (group II). One patient had positive both serum and BAL samples (group III). Fifteen GM positive patients (9 from group I, group II, and III) were categorized as probable IPA. Thirty-six patients (40%) negative for GM (group IV) were considered with a possible IPA. IPA was excluded in 38 patients (42.2%) (group V). Anti-mould therapy was initiated in all 15 patients who were considered to be cases with probable IPA. IPA was the immediate cause of death in 3 cases (25%).Conclusions: Our results demonstrated the clinical applicability of the GM test for screening of IPA in high-risk patients with hematological malignancies and HSCT.</p>
					<p><a href="https://foliamedica.bg/article/65248/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/65248/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Fri, 31 Dec 2021 10:30:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Liquid Biopsy – Possibilities for Monitoring the Therapeutic Response in Non-Small Cell Lung Cancer</title>
		    <link>https://foliamedica.bg/article/68216/</link>
		    <description><![CDATA[
					<p>Folia Medica 63(6): 839-846</p>
					<p>DOI: 10.3897/folmed.63.e68216</p>
					<p>Authors: Gabriela A. Raycheva, Hristo Y. Ivanov, Zhanet G. Grudeva-Popova</p>
					<p>Abstract: Lung cancer is the leading cause of death from malignancy worldwide. Its heterogeneity and tumour biology make treatment considerably more difficult. The introduction of target molecules heralded the beginning of the personalized medicine which tailors medical treatments to the molecular and genetic profile of a patient. Liquid biopsy is an innovative, non-invasive method which is used both for diagnostic purposes and for therapeutic monitoring. Liquid biopsy has the potential to help manage non-small cell lung cancer throughout all stages of this cancer: screening, detection of minimal residual disease to guide adjuvant treatment, early detection of relapse, systemic treatment initiation, monitoring of response to targeted or immune therapy, and the emergence of resistance to applied treatment. At present, the study of circulating tumour DNA is used in clinical practice, but circulating tumour cells, miRNAs, exosomes, and platelets formed in the tumour also show promising results.</p>
					<p><a href="https://foliamedica.bg/article/68216/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/68216/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Invited Review</category>
		    <pubDate>Fri, 31 Dec 2021 10:30:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Does dihydropyrimidine dehydrogenase level modify plasma antioxidant capacity in colorectal cancer patients treated with fluoropyrimidines? </title>
		    <link>https://foliamedica.bg/article/57234/</link>
		    <description><![CDATA[
					<p>Folia Medica 63(5): 760-767</p>
					<p>DOI: 10.3897/folmed.63.e57234</p>
					<p>Authors: Velko Minchev, Nadya Hristova-Avakumova, Kalina Kamenova, Liliya Atanasova, Marin Angelov, Lozan Todorov, Slavina Surcheva, Rumen Nikolov</p>
					<p>Abstract: Introduction: Colorectal cancer is the third most common cancer type worldwide. Fluoropyrimidines and their prodrug-based regimens are widely applied as primary medications. The main enzyme responsible for the rate-limiting step in pyrimidine and for the 5-fluorouracil catabolism is dihydropyrimidine dehydrogenase (DPD).Aim: We aimed to screen DPD level and the changes of plasma antioxidant capacity of colorectal cancer patients on 5-fluorouracil regimen. Materials and methods: Human DPD Elisa Kit based on sandwich enzyme-linked immune-sorbent assay and spectrophotometric methods (FRAP and ABTS) were used in the study.Results: No statistically significant changes in plasma scavenging activity according to the results obtained in the ABTS system have been observed after evaluating all patients and considering DPD concentration. A decrease of the ferric reducing ability of patients&rsquo; plasma taken after the administered treatment was found. The increase of DPD level is accompanied by a decrease in the p values and therefore the statistical significance of the differences increases.Conclusions: Based on the aforementioned observations, it could be concluded that some aspects of plasma antioxidant capacity and individuals&rsquo; antioxidant status might be involved in the pathogenesis of the disease and could be altered by the activity of some enzymes. The cancer therapy in question, by the specificity of its mechanism of action, can modify patient&rsquo;s oxidative status.</p>
					<p><a href="https://foliamedica.bg/article/57234/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/57234/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Sun, 31 Oct 2021 17:00:17 +0000</pubDate>
		</item>
	
		<item>
		    <title>Clinical characteristics, disease evolution and survival in patients with chronic myeloid leukemia, BCR-ABL1 (+) and T315I mutation.</title>
		    <link>https://foliamedica.bg/article/63366/</link>
		    <description><![CDATA[
					<p>Folia Medica 63(5): 670-675</p>
					<p>DOI: 10.3897/folmed.63.e63366</p>
					<p>Authors: Veselina Goranova-Marinova, Alexander Linev, Hristo J. Ivanov, Ivan Zheljazkov, Vily Stoyanova, Zhanet Grudeva-Popova</p>
					<p>Abstract: Introduction: The T315I mutation in patients with chronic myeloid leukemia (CML) has been associated with therapeutic resistance and an unfavourable prognosis.Aim: To study the frequency of T315I mutation in patients with CML, BCR-ABL (+), their clinical characteristics, disease evolution, and median survival.Patients and methods: We studied 75 patients with CML and BCR-ABL1 (+). T315I mutation was detected by digital droplet PCR and BCR-ABL1 was analyzed by RT-PCR. A comparative analysis was performed by sex, age, disease phase, risk group, treatment, molecular response (MR), and median survival in T315I (+) and T315I (&minus;) patients.Results: T315I mutation was detected in 11 patients (14.7%). No significant difference was found in the phase, risk group, and first-line therapy. A significantly higher proportion of T315I (+) did not achieve MR &gt;3.5 log: 8 (72.7%) vs. 22 (34.4%) (p=0.023). The lowest mean BCR-ABL1 levels were significantly higher in the CML T315I (+) group compared to the CML T315I (&minus;) group: 12.1&plusmn;6.0 vs. 3.77&plusmn;1.28 (p=0.009). The median survival of T315I (+) patients was significantly shorter: 73 months vs. 175 months (p&lt;0.0001, CI 95%).Conclusions: Our data confirm the world experience on the frequency of T315I mutation, including the unfavourable evolution, resistance to TKI treatment and short survival. ddPCR is a highly sensitive method for early detection of genetic mutations which gives the chance for effective treatment.</p>
					<p><a href="https://foliamedica.bg/article/63366/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/63366/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Sun, 31 Oct 2021 17:00:06 +0000</pubDate>
		</item>
	
		<item>
		    <title>L3 rootlet recurrent melanocytic schwannoma – case report and literature review</title>
		    <link>https://foliamedica.bg/article/55295/</link>
		    <description><![CDATA[
					<p>Folia Medica 63(3): 448-456</p>
					<p>DOI: 10.3897/folmed.63.e55295</p>
					<p>Authors: Georgi K. Georgiev, Ivan V. Todorov, Todor P. Shamov, Ivan V. Krushovenski, Albena D. Fakirova, Boryana N. Ilcheva, Iliyan T. Georgiev, Nikolai D. Georgiev, Vladimir S. Prandjev, Tihomir N. Eftimov</p>
					<p>Abstract: First described by Miller in 1932, melanocytic schwannoma (MS) (melanotic schwannoma, pigmented schwannoma) is a rare variation of peripheral nerve sheet tumours with ectodermal origin occurring predominantly in somatic, but also in the autonomic peripheral system with around two hundred cases in the literature. Predominantly benign tumours, MS are still imaging and pathological challenge and can be easily misdiagnosed with more aggressive peripheral nerve tumours.We report a case of melanocytic schwannoma on L3 sensory rootlet with systematic literature review of nearly 200 cases presented in intracranial, paraspinal region, thoracic, abdominal or pelvic cavities and skin. Two-thirds of cases are part of Carney complex.We present a case of a 61-year-old male with a 3-month history of low back pain, progressive numbness and stiffness in the right thigh, shin and knee, tibial and peroneal paresis causing gait disturbance and neurological claudication. MRI findings present &ldquo;sand clock&rdquo; type intradural extramedullary tumour formation with extension to the L3 rootlet through right L3-L4 foramen, hypointense on T2 and hyperintense on T1. Pathological diagnosis of sporadic type melanocytic schwannoma was made via immunohistological and ultrastructural analysis. Thirteen months after total resection there was clinical and MRI evidence of recurrence of the tumour. Total resection and radiosurgery was performed with a recurrence free period of 14 months.A gold standard for melanocytic schwannoma treatment is gross total surgical resection. Despite being considered benign tumours, MS have a local or metastatic recurrence of around 13%. MRI imaging in most of the cases is insufficient and only exhaustive pathological and immunohistological examination is the key to diagnosis. Need of postoperative radiation therapy is still controversial. For the first time, a criterion for postoperative adjuvant therapy was established.</p>
					<p><a href="https://foliamedica.bg/article/55295/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/55295/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Wed, 30 Jun 2021 21:00:21 +0000</pubDate>
		</item>
	
		<item>
		    <title>A rare case of primary adrenal lymphoma</title>
		    <link>https://foliamedica.bg/article/55651/</link>
		    <description><![CDATA[
					<p>Folia Medica 63(3): 443-447</p>
					<p>DOI: 10.3897/folmed.63.e55651</p>
					<p>Authors: Alexey V. Shabunin, Dmitry N. Grekov, Ivan N. Lebedinsky, Andrey I. Evsikov, Serghei Covantev, Varvara A. Afanaseva</p>
					<p>Abstract: Adrenal gland incidentaloma (incidental &ndash; sudden, accidental) is a mass of the adrenal gland(s), accidentally detected by an instru-mental examination conducted for other reasons. The frequency of detection of this pathology based on computer tomography of the abdominal organs is 0.5%&ndash;2%. In most cases, the mass is represented by adrenocortical adenomas without hormonal secretion. It is an extremely rare case (less than 1% of all cases) when the adrenal incidentaloma is a primary adrenal lymphoma, which accounts for 1% of all non-Hodgkin lymphomas and 3% of all extranodal lymphomas with a few cases reported in the literature. In our article, we present a case of left adrenal incidentaloma of the adrenal gland, which, during further observation and examination, increased in size, which was the reason for performing laparoscopic adrenalectomy. According to the results of the histological examination, the mass turned out to be diffuse large B-cell lymphoma.</p>
					<p><a href="https://foliamedica.bg/article/55651/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/55651/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Wed, 30 Jun 2021 21:00:20 +0000</pubDate>
		</item>
	
		<item>
		    <title>Radiation-induced low grade fibromyxoid sarcoma of the larynx: a case report and literature review</title>
		    <link>https://foliamedica.bg/article/56150/</link>
		    <description><![CDATA[
					<p>Folia Medica 63(3): 433-437</p>
					<p>DOI: 10.3897/folmed.53.e56150</p>
					<p>Authors: Dariya L. Chivchibashi, Pavel Pavlov, Maria Tzaneva, Nikolay Sapundzhiev, Georgi Davidov</p>
					<p>Abstract: Low grade fibromyxoid sarcoma (LGFMS) is an uncommon variant of fibrosarcoma with high risk of local recurrence, immense metastatic potential and frequently protracted period between tumour presentation and metastasis. This unusual malignancy rarely affects the region of the head and neck which makes cases of laryngeal LGFMS extremely infrequent. To date, LGFMS of the larynx has been scatteredly mentioned in the literature. Neither incidence nor causes and risk factors for laryngeal LGFMS have been clarified so far. To the authors&rsquo; knowledge, this is the first case report that discusses the clinical course, imaging diagnosis, histopathological evaluation and surgical approach to radiation-induced laryngeal LGFMS.We present a case of a 70-year-old man who developed a LGFMS after previous radiotherapy (RT) for squamous cell carcinoma (SCC) of the larynx. The latency period between the time of radiation exposure and the diagnosis of LGFMS was twenty-seven months. After re-confirming the diagnosis with second biopsy and extensive imaging evaluation the patient was subjected to an open partial resection of the larynx. Owing to the rarity of the tumour, there is no established protocol with follow-up recommendations.This case highlights the importance of considering the RT history of the patient in order to monitor radiotherapy-related complications, including the occurrence of LGFMS.</p>
					<p><a href="https://foliamedica.bg/article/56150/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/56150/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Wed, 30 Jun 2021 21:00:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Portal vein reconstruction during pancreaticoduodenal resection using an internal jugular vein as a graft</title>
		    <link>https://foliamedica.bg/article/55650/</link>
		    <description><![CDATA[
					<p>Folia Medica 63(3): 429-432</p>
					<p>DOI: 10.3897/folmed.63.e55650</p>
					<p>Authors: Gancho Kostov, Rossen Dimov</p>
					<p>Abstract: Portal vein involvement by malignant tumours of the head of the pancreas is observed in almost 50% of the patients. In the past, this finding usually rendered the tumor inoperable. Over the past 30 years, the operative morbidity and mortality rate of pancreatectomy combined with portal vein resection has greatly decreased, and portal vein resection in pancreatic surgery has become a well-tolerated operative procedure in large-volume centres. Options for a venous reconstruction after SMV/PV resection include prosthetic, autologous or cryopreserved cadaveric vein grafts.Vascular resection and reconstruction provides great opportunity for R0 resection and improvement of oncological results in patients with pancreatic tumors and involvement of venous vessels, in the absence of distant metastases. If a longer graft length is required, there is the option of using either synthetic prosthesis or cryopreserved grafts. Their weak sides can be avoided by the use of jugular vein graft. Portal vein resection will be performed more often, safely and aggressively over the next years.</p>
					<p><a href="https://foliamedica.bg/article/55650/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/55650/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Wed, 30 Jun 2021 21:00:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Primary gastric melanoma of unknown origin: a case report and short literature review</title>
		    <link>https://foliamedica.bg/article/53726/</link>
		    <description><![CDATA[
					<p>Folia Medica 63(2): 282-286</p>
					<p>DOI: 10.3897/folmed.63.e53726</p>
					<p>Authors: Athena Myrou, Theodoros Aslanidis, Andreas Protopapas, Elisavet Psoma, Andreas Kontosis, Triantafyllia Koletsa</p>
					<p>Abstract: Though being usually a cutaneous tumor, melanomas can occur in several extracutaneous sites. Primary mucosal melanomas are rare, and primary gastric mucosal melanomas are considered extremely rare. Compared with cutaneous and ocular melanoma, mucosal melanomas have the lowest five-year survival. High level of suspicion of such rare condition may be the only way for early detection, diagnosis and chance for successful management of similar cases. In the present report, a case of a primary gastric melanoma in a 73-year-old man is described, along with a short review of the literature</p>
					<p><a href="https://foliamedica.bg/article/53726/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/53726/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Fri, 30 Apr 2021 10:00:18 +0000</pubDate>
		</item>
	
		<item>
		    <title>Age and sex do not affect first year recurrence in patients with non-muscle invasive bladder cancer</title>
		    <link>https://foliamedica.bg/article/53234/</link>
		    <description><![CDATA[
					<p>Folia Medica 63(2): 242-246</p>
					<p>DOI: 10.3897/folmed.63.e53234</p>
					<p>Authors: Huseyin Kocan, Mustafa Kadihasanoglu</p>
					<p>Abstract: Introduction: Although demographic heterogeneity in the management of patients with non-muscle invasive bladder tumor (NMIBT) is an important factor, there are only minimal evidence-based recommendations that adjust for patient age and gender. The relationship and impact of age and gender on the recurrence in NBIMT is poorly investigated and understood.Aim: The aim of the study was to evaluate the impact of age and sex on the recurrence of non-muscle invasive bladder cancer.Materials and methods: Patients treated with transurethral resection (TUR) of primary NMIBT were included in the study. Risk calculation was made according to the European Organization for Research and Treatment of Cancer (EORTC) risk tables. Prognostic factors for predicting tumor recurrence up to 5 years including age and sex were analyzed. The Mann-Whitney U test was used for comparison of non-parametric variables in independent groups. Kaplan-Meier method, with log rank (Mantel-Cox) analyses applied for comparison of mean duration of remission by sex and age, was used to calculate mean duration of remission. Results: A total of 81 patients, 68 males (mean age 59.03 years) and 13 females (mean age 58.13 years) were eligible for final analysis. Mean survival time of patients &lt;60 years old and older was 17.3&plusmn;2.1 months (13.2&ndash;21.3) and 17.9&plusmn;2.8 months (12.4&ndash;23.4), respectively (p=0.6). Mean survival time was 17.3&plusmn;2.1 months for females and 15.4&plusmn;2.1 months for males (p=0.08). However, 1-year tumor-free rate of female patients (53.8%) was not much different from that of males (31%) (p=0.11). Although considerable difference was observed between recurrence rates of patients according to sex, it failed to reach statistical significance.Conclusions: The results of the present study suggest that the recurrence of NMIBT is not associated with age or gender.</p>
					<p><a href="https://foliamedica.bg/article/53234/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/53234/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Fri, 30 Apr 2021 10:00:12 +0000</pubDate>
		</item>
	
		<item>
		    <title>Regioselective synthesis of triazolo[3,4-e]purine derivatives and their anti-cancer activity against NCI-60 cell-lines</title>
		    <link>https://foliamedica.bg/article/52891/</link>
		    <description><![CDATA[
					<p>Folia Medica 63(2): 213-220</p>
					<p>DOI: 10.3897/folmed.63.e52891</p>
					<p>Authors: Khushal Kapadiya, Kishor Kavadia, Jyoti Gohel, Ranjan Khunt</p>
					<p>Abstract: Introduction: Due to the vast medicinal importance of purine nucleoside, a hybrid molecule of triazole with purine ring might explode a lead molecule in the pharma sector and based on the last decade&rsquo;s studies suggested that the nitrogen-rich molecules possess a wide range of medicinal importance.Aim: Due to the vast application of purine nucleoside itself in the field of cancer research, we synthesized triazolo[3,4-e]purines and screened them for their anti-cancer study against NCI-60 cell lines by the protocol used by NIH.Materials and methods: The targeted molecules, 4-chloro-5a,6-dihydro-8-substitutedphenyl-1H-[1,2,4]triazolo[3,4-e]purine derivatives (4a-4h) were synthesized in a two-step procedure by nucleophilic substitution (SN) at C-2 chlorine followed by formation of the triazole ring by acid-catalyzed reaction in the polar protic solvent.Results: It was observed that the regioselective approach followed in C-2 chlorine replacement instead of C-6 chlorine during SN reaction. One-dose response of selected three molecules (4a, 4b, and 4c) showed that 4b (K-562: 64.47 &micro;M &amp; SR: 63.38 &micro;M; mean GI50: 99.09 &micro;M) was found to be more potent than 4a and 4c.Conclusions: We have described in this study the general synthetic method for triazolo[3,4-e]purines as an innovative class of potential anticancer agents. The dose-response curve in the sense of mean GI50 for three compounds across all 60 cell lines, 4b can be served as lead after necessary modification.</p>
					<p><a href="https://foliamedica.bg/article/52891/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/52891/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Fri, 30 Apr 2021 10:00:08 +0000</pubDate>
		</item>
	
		<item>
		    <title>Recent Advances in the Development of PI3K/mTOR-Based Anticancer Agents: A Mini Review</title>
		    <link>https://foliamedica.bg/article/52791/</link>
		    <description><![CDATA[
					<p>Folia Medica 63(1): 7-14</p>
					<p>DOI: 10.3897/folmed.63.e52791</p>
					<p>Authors: Ishan Panchal, Archana Navale, Ashish Shah, Sandip Badeliya, Rati Tripathi</p>
					<p>Abstract: Cancer refers to the group of diseases characterized by uncontrolled growth of abnormal cells. It spreads throughout the body which makes this disease one of the huge global threats to mankind. Intensive research over the years has established deregulation of mam-malian target of rapamycin pathway in cancer. This has led to the development of mammalian target of rapamycin inhibitors. Several inhibitors of the mammalian target of rapamycin are under preclinical and early clinical trials. Researchers have investigated a series of furoquinoline, phenyl sulphonylureas, 4-acrylamido-quinoline, pyrazolochalcones, imidazole [4,5-b] pyridine, thienopyrimidine, aminopyrimidin scaffolds in the last three years. This review provides comprehensive information and critical discussions on designing of novel selective inhibitors of mammalian target of rapamycin with superior activity in the treatment of cancer.</p>
					<p><a href="https://foliamedica.bg/article/52791/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/52791/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Invited Review</category>
		    <pubDate>Sun, 28 Feb 2021 17:57:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Brain Metastases from Non-small-cell Lung Carcinoma – CyberKnife Re-irradiation after Gamma Knife Radiosurgery</title>
		    <link>https://foliamedica.bg/article/52182/</link>
		    <description><![CDATA[
					<p>Folia Medica 62(4): 856-860</p>
					<p>DOI: 10.3897/folmed.62.e52182</p>
					<p>Authors: Veselin Popov</p>
					<p>Abstract: Lung cancer is the most common neoplasia and the most common cause of cancer mortality. The condition is usually diagnosed at a locally advanced or metastatic stage, which is a bad prognostic factor. Around 40% of all oncology patients with brain metastases have lung cancer.Modern linear accelerators allow clinicians to perform radiosurgery and deliver a high radiation dose to low volume with a high dose gradient. Herein we present a 55-year-old male patient who received radiosurgery four times over three years &ndash; two times with Gamma Knife and two times with CyberKnife. Re-irradiation gives the opportunity to treat a local progression of a metastasis, which already has been irradiated. A series of control brain magnetic resonance imaging confirmed a good local control of treated lesions with no necrosis in surrounding healthy tissue or significant oedema. The neurological symptoms were completely controlled and the quality of life of the patient improved considerably. Radiosurgery is a prevalent, non-invasive, painless method of treatment with proven clinical results. It may be reused as long as it has clinical benefits to the patient.</p>
					<p><a href="https://foliamedica.bg/article/52182/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/52182/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Thu, 31 Dec 2020 20:00:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>A Collision between Cavernous-Capillary Hemangioma with Stromal Luteinization and Serous Cystadenoma</title>
		    <link>https://foliamedica.bg/article/51551/</link>
		    <description><![CDATA[
					<p>Folia Medica 62(4): 851-855</p>
					<p>DOI: 10.3897/folmed.62.e51551</p>
					<p>Authors: Spasimir T. Shopov</p>
					<p>Abstract: A collision tumor represents a coexistence of two adjacent but histologically distinct tumors without histologic admixture in an organ. Serous tumors of the ovary are the most common forms of epithelial tumors, and cavernous hemangiomas are rare in the ovary. Howev-er, a collision between them is an extremely rare pathology. Here the author presents a report of a 74-year-old woman whose ultrasound examines establishes rounded left ovary formation with hypo- and hyperdense sections. Paraclinical: CA125 within normal range. Serum levels free testosterone 3.79 nmol/l (normal 0.49-2.64 nmol/l for women). The histology showed benign serous cystadenoma and vascular lesions composed of capillary and cavernous vessels amongst luteinized stromal cells. The luteinized cells were positive for inhibin A. The endothelial cells were negative for estrogen and progesterone receptor. A search was conducted in the Medline database via PubMed using the terms: &lsquo;hemangioma&rsquo;, &lsquo;ovary&rsquo;, &lsquo;collision&rsquo;, &lsquo;serous cystadenoma&rsquo;, no more than 70 articles for ovarian hemangiomas appeared, and no articles for a collision between serous cystadenoma and mixed hemangioma with stromal luteinization in the ovary. From the reference, this is the first reported case of collision between serous cystadenoma and mixed cavernous-capillary hemangioma with stromal luteinization in the ovary. This rare case of collision between tumors in the ovary sheds light on possible tumor pathology in the woman&rsquo;s reproductive system, which must be considered by gynaecologists and pathologists.</p>
					<p><a href="https://foliamedica.bg/article/51551/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/51551/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Thu, 31 Dec 2020 20:00:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Does Chronic Low-grade Systemic Inflammation Change Tumor Markers Levels in Patients on Hemodialysis?</title>
		    <link>https://foliamedica.bg/article/51457/</link>
		    <description><![CDATA[
					<p>Folia Medica 62(4): 838-842</p>
					<p>DOI: 10.3897/folmed.62.e51457</p>
					<p>Authors: Gilmar Pereira Silva, Vítor Pereira Xavier Grangeiro, Carmelita Félix Dantas de Oliveira</p>
					<p>Abstract: Introduction: End-stage renal disease (ESRD) patients are known to have a high risk of developing cancer-related inflammation. Elevated serum levels of tumor markers in ESRD/hemodialysis patients makes analysis and interpretation difficult. Aim: To verify the possible relationship between chronic low-grade systemic inflammation serum levels determined by C-reactive protein (CRP) and the tumor biomarkers in patients on hemodialysis. Materials and methods: A prospective study of prevalence was conducted in the Hemodialysis Sector of the University Hospital of the University of Bras&iacute;lia between July 2016 and December 2016 in men aged 18 to 60 years without clinically detectable cancer. We assessed inflammation by serum high-sensitivity CRP test (hs-CRP) and serum tumor in the case groups and controls. The hemodialysis group was split into two subgroups: group 1: patients with inflammation (CRP &gt; 5 mg/L, n=27), and group 2: patients without inflam-mation (CRP &le;5 mg/L, n=33).Results: There was no significant difference in age mean levels between case groups and controls (44.00&plusmn;08.00 vs. 41.00&plusmn;07.00, p=0.08). There was no difference or correlation (p&gt;0.05) between tumor markers levels and patients with and without inflammation. Conclusions: The results of this study suggest that chronic low-grade systemic inflammation defined by C-reactive protein serum levels does not promote elevated serum PSA levels in chronic hemodialysis patients.</p>
					<p><a href="https://foliamedica.bg/article/51457/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/51457/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Short Communication</category>
		    <pubDate>Thu, 31 Dec 2020 20:00:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Postoperative Low Molecular Weight Heparin-induced Infection in Gastrointestinal Cancer Patients. A 2-year Single Centre Experience </title>
		    <link>https://foliamedica.bg/article/50576/</link>
		    <description><![CDATA[
					<p>Folia Medica 62(4): 769-776</p>
					<p>DOI: 10.3897/folmed.62.e50576</p>
					<p>Authors: Alexandrina Nikova, Maria Kyriazi, Helena Michalopoulou, Melani Demetriou, Vasilis Tselepidis, Konstantinos Ntatsis</p>
					<p>Abstract: Introduction: Patients with gastrointestinal cancer are at high risk of developing thrombosis and postoperative infection. Antico-agulation therapy for such patients is provided by low molecular weight heparin (LMWH) and elastic stockings. The latter, however, is linked to immunoregulatory activities and immunosuppression in vivo and in vitro.Aim: Therefore, the present study aimed to examine the link between LMWH and infection in patients with gastrointestinal cancer.Materials and methods: The study is a retrospective report of 51 patients operated on at the Second Department of Surgery at Metaxa Cancer Hospital. The sample was divided into groups based on the presence or absence of diabetes and preoperative anticoagu-lation therapy. Afterwards, the data were statistically analysed. Results: The results of the study show a statistically significant correlation between LMWH and infection. Moreover, the risk of infec-tion increases by 13.3% for each day of heparin intake. The theory of this correlation is explained in detail. Conclusions: The findings of the present study raise an essential question about postoperative management of cancer patients. How-ever, the study sample size is rather small so further studies with larger sample size are required to give greater credence to results.</p>
					<p><a href="https://foliamedica.bg/article/50576/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/50576/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Thu, 31 Dec 2020 20:00:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Endobronchial Ultrasound Transbronchial Needle Aspiration for the Diagnosis of Paratracheal and Peribronchial Central Parenchymal Lesions</title>
		    <link>https://foliamedica.bg/article/51230/</link>
		    <description><![CDATA[
					<p>Folia Medica 62(4): 690-694</p>
					<p>DOI: 10.3897/folmed.62.e51230</p>
					<p>Authors: Nikolay Yanev, Evgeni Mekov, Dimitar Kostadinov</p>
					<p>Abstract: Objectives: Obtaining qualitative, sufficient material for the diagnosis of malignancies in cases with normal endoscopic findings in patients with suspected lung cancer and hilar and mediastinal lymphadenopathy is challenging.Materials and methods: Endobronchial ultrasound (EBUS) was used to control a transbronchial needle biopsy (&#1058;BNA) for the first time in our country. From 2015 to 2018, TBNA with a convex probe EBUS was performed on 57 patients [41 men, 16 women, mean age 56.10 (range 37-77 years)] with mediastinal lesions found on CT scan. We used the Hitachi Aloka - ProSound Alpha 7 and BF-UC180F (Olympus) 21G and 22G needles Ultrasound System. In 22 of the cases, we performed a biopsy of hilum lesions (9 on the left and 13 on the right), in 13 - of subcarinal lesions, and in 4 - of lesions located on the right paratracheal lymphatic chain. Results: EBUS-TBNA confirmed lung cancer in 48 patients (84.2%). In 33 of them, it was non-small cell lung cancer: spinocellular in 13 cases and adenocarcinoma in 17 cases; three cases were without accurate verification. Small cell lung cancer was found in 15 cases. In two cases, the biopsies were negative for tumor (3.5%), and in seven - non-specific inflammatory process (12.3%). Conclusions: This study confirms the high diagnostic success rate of EBUS-TBNA reported in similar studies developed on a daily routine basis without adhering to a specific protocol. EBUS-TBNA is an interventional procedure with high sensitivity in diagnosing hilar and mediastinal lesions in negative conventional bronchoscopy and thus is useful in patients with paratracheal and peribronchial lesions. The results could be improved with training and experience.</p>
					<p><a href="https://foliamedica.bg/article/51230/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/51230/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Thu, 31 Dec 2020 20:00:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Cancer-related Fatigue in Patients with Oncological Diseases: Causes, Prevalence, Guidelines for Assessment and Management</title>
		    <link>https://foliamedica.bg/article/50517/</link>
		    <description><![CDATA[
					<p>Folia Medica 62(4): 679-689</p>
					<p>DOI: 10.3897/folmed.62.e50517</p>
					<p>Authors: Raisa Strebkova</p>
					<p>Abstract: Fatigue and exhaustion are considered to be the most common complaints of patients with cancer during treatment and upon its completion. The manifestations of fatigue can be physical, cognitive, and emotional. The exact determinants of fatigue, however, are yet unknown. An initial literature review was conducted. Four reference databases were searched (MEDLINE, ELSEVIER &ndash; Science Direct, ELSEVIER &ndash; SCOPUS, Springer). The initial search yielded 430 articles. We included references consistent with the study design, pub-lished between 1993 and 2017, and written in English or German. The 48 remaining articles were assessed for relevance to the area by visually examining their titles for keywords: cancer-related fatigue, assesment, management. Cancer-related fatigue in cancer patients during treatment and in survivors is estimated to have a prevalence in the range of 58% to 90%. This report is a review of the literature relevant to the problem of fatigue in patients with oncological diseases &ndash; causes, prevalence, and impact on the lives of affected patients, proposing guidelines for assessment and management. A set of reliable tools have been presented for assessment and measurement of the burden of fatigue. The management strategies include a number of non-pharmacological methods: physically based therapies, psycho-educational and mind-body interventions, methods of managing sleep disorders, methods of increasing physical activity, and pharmacological modalities. Clarification of the causes for fatigue, its detection, a reliable assessment of its severity, the application of appropriate interventions for treatment and the necessary care could support the application of a differentiated approach.</p>
					<p><a href="https://foliamedica.bg/article/50517/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/50517/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Invited Review</category>
		    <pubDate>Thu, 31 Dec 2020 20:00:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Pharmacotherapeutic Considerations for Use of Cannabinoids to Relieve Symptoms of Nausea and Vomiting Induced by Chemotherapy</title>
		    <link>https://foliamedica.bg/article/51478/</link>
		    <description><![CDATA[
					<p>Folia Medica 62(4): 668-678</p>
					<p>DOI: 10.3897/folmed.62.e51478</p>
					<p>Authors: Tijana Serafimovska, Marija Darkovska-Serafimovska, Gjoshe Stefkov, Zorica Arsova-Sarafinovska, Trajan Balkanov</p>
					<p>Abstract: Patients suffering from malignant diseases receive very often highly emetogenic chemotherapy as part of their treatment. With the aim of assessing the efficacy of cannabinoids in treating chemotherapy-induced nausea and vomiting (CINV), we searched the literature published until April 2020 in Medline/PubMed, Embase, the Cochrane Controlled Trials Register, and in specific web pages. Randomized clinical trials comparing cannabinoids efficacy in managing CINV with that of placebo reported absence of vomit-ing (3 trials, 168 patients) and absence of nausea and vomiting (3 trials, 288 participants). In comparison with patients receiving other antiemetics, patients receiving cannabinoids reported no nausea (5 trials, 258 participants), no vomiting (4 trials, 209 participants), and absence of both (4 trials, 414 patients). Across all trials, cannabinoids were more effective in relieving the symptoms of nausea and vomiting induced by cytotoxic therapy than placebo was and slightly better than conventional antiemetics. A retrospective review com-paring nabilone, dronabinol, delta-9-THC, and delta 8-THC with other antiemetics used to manage CINV in pediatric patients showed that these drugs could also be used as adjuvant antiemetics. Cancer patients on highly emetogenic chemotherapy but with insufficiently effective standard antiemetic therapy can be given cannabis preparations containing similar amounts of tetrahydrocannabinol and can-nabidiol, which should be received in strict compliance with the professional guidelines for the treatment of CINV.</p>
					<p><a href="https://foliamedica.bg/article/51478/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/51478/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Invited Review</category>
		    <pubDate>Thu, 31 Dec 2020 20:00:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Vaginal Mucosal Melanoma: a Complete Remission after Immunotherapy and &#039;0-7-21&#039; Radiotherapy Regimen (24 Gy/3 fractions/21 days)</title>
		    <link>https://foliamedica.bg/article/49926/</link>
		    <description><![CDATA[
					<p>Folia Medica 62(3): 605-609</p>
					<p>DOI: 10.3897/folmed.62.e49926</p>
					<p>Authors: Silvana Parisi, Sara Lillo, Alberto Cacciola, Anna Santacaterina, Carmela Palazzolo, Angelo Platania, Nicola Settineri, Tindara Franchina, Consuelo Tamburella, Stefano Pergolizzi</p>
					<p>Abstract: We present the case of a patient with vaginal mucosal melanoma who underwent complete remission after immunotherapy and &lsquo;0-7-21&rsquo; radiotherapy regimen (24 Gy/3 fractions/21 days). An 80-year-old woman had a biopsy of a voluminous vaginal lesion and received a histological diagnosis of melanoma with angiomatoid aspects. The patient underwent immunotherapy with pembrolizumab 2 mg/kg every 3 weeks and was sent to our attention for planning radiotherapy as the extent of the lesion did not make it susceptible to surgery.Considering the concomitant administration of pembrolizumab, we chose to treat this patient with a modulated intensity radiation therapy technique delivering a hypofractionated dose of 24 Gy in 3 fractions delivered on days 0, 7, and 21. We observed a complete clinical remission of the melanoma 12 months after radiotherapy and she has been alive for 18 months with no clinical signs of local recurrence.</p>
					<p><a href="https://foliamedica.bg/article/49926/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/49926/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Wed, 30 Sep 2020 17:40:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Are Daily Life Activities of Patients with Proximal Femoral Tumor Resection Prosthesis as Good as those of Patients Undergoing Total Hip Prosthesis for Non-Tumor Causes?</title>
		    <link>https://foliamedica.bg/article/47150/</link>
		    <description><![CDATA[
					<p>Folia Medica 62(3): 497-502</p>
					<p>DOI: 10.3897/folmed.62.e47150</p>
					<p>Authors: Ismail Burak Atalay, Recep Öztürk, Aliekber Yapar, Coşkun Ulucakoy, Eray Ertürk Engin, Bedii Şafak Güngör</p>
					<p>Abstract: Introduction: The Barthel Index of Activities of Daily Life (ADL) is a scale used to evaluate performance in daily life activities and investigate the reason and resulting relationships in a comprehensive, non-biased manner.Aim: The aim of this study was to compare the daily life activities of patients who underwent proximal femoral tumor resection prosthesis assessed by the Barthel Index with the activities of daily living of patients with a total hip prosthesis performed for non-tumor reasons.Materials and methods: Twenty-eight patients were included in the study. Sixteen patients underwent hip prosthesis for reasons other than tumor (femur proximal avascular necrosis, coxarthrosis, etc.) and 12 underwent wide resection and femur proximal tumor resection prosthesis due to primary malignant bone tumor or metastasis in the proximal femur. The Barthel Index was used to evaluate their life quality at 3 months.Results: A total of 28 patients (mean age 60.9&plusmn;1.4 yrs, range 19.0-84.0, 17 female and 11 male patients) were included into the study. Mean ADL score was 84.5&plusmn;20.6 (5&ndash;100.0). While only one patient was totally dependent in terms of daily life activities, 8 other patients were totally independent. When the patient groups were categorized by degree of dependency according to the ADL scores, it was found that dependency states of the two surgery groups were similar in distribution (p=0.212, p=0.703, and p=1.000 respectively).Conclusion: Functional recovering levels were good in the patients who underwent a surgery for proximal femoral tumor resection prosthesis; there was no significant difference when we compared the functional level after total hip prosthesis applied for non-tumor reasons.</p>
					<p><a href="https://foliamedica.bg/article/47150/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/47150/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Wed, 30 Sep 2020 17:40:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>The Conundrum of Prematurity and Pregnancy Outcomes after Fertility Sparing Treatment Modalities for Early Stage Cervical Cancer:  A Systematic Review of the Literature</title>
		    <link>https://foliamedica.bg/article/48736/</link>
		    <description><![CDATA[
					<p>Folia Medica 62(3): 453-461</p>
					<p>DOI: 10.3897/folmed.62.e48736</p>
					<p>Authors: Anastasios Pandraklakis, Nikolaos Thomakos, Anastasia Prodromidou, Maria D. Oikonomou, Ioannis G. Papanikolaou, Dimitrios-Efthimios G. Vlachos, Dimitrios Haidopoulos, Georgios Daskalakis, Alexandros Rodolakis</p>
					<p>Abstract: Advances in modern medicine have allowed patients with early stage cervical cancer (stages Ia - IIai) to preserve their fertility with oncologic efficacy comparable to previous radical treatments. A variety of conservative-fertility sparing procedures, also known as Fertility Sparing Surgeries (FSS) have been proposed. The present review aimed to provide the current evidence on obstetric outcomes and the prematurity rates as well as to discuss the management modalities of these high-risk pregnancies. Our review of the literature included 3042 women with early cervical cancer, of whom 2838 underwent FSS (204 excluded for oncologic reasons). Almost half of these patients attempted to become pregnant and about two thirds of them achieved at least one pregnancy either spontaneously or with the help of Assisted Reproduction Technologies. Data revealed that 63.9% of these pregnancies resulted in live births, whereas 37.6% of them were preterm. The main cause of preterm births in this subpopulation is the postoperative cervical length restriction that consequently leads to cervical incompetence and ascending infections that eventually lead to (clinical or subclinical) chorioamnionitis. Radical operations such as ART, VRT and MIRT presented with higher prematurity rates. The lack of standardized protocols for the management of pregnancies after FSS precluded reaching to firm results with regards to the efficacy of them in achieving favourable obstetrical outcomes. Further large volume studies are warranted with the intent to acquire standardized guidelines for pregnancies achieved after FSS for early stage cervical cancer.</p>
					<p><a href="https://foliamedica.bg/article/48736/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/48736/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Invited Review</category>
		    <pubDate>Wed, 30 Sep 2020 17:40:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Elderly Patients with Gynecological Cancer: Is the Management Individualized?</title>
		    <link>https://foliamedica.bg/article/47920/</link>
		    <description><![CDATA[
					<p>Folia Medica 62(3): 438-443</p>
					<p>DOI: 10.3897/folmed.62.e47920</p>
					<p>Authors: Christos Iavazzo, George Iatrakis, Paraskevi-Evangelia Iavazzo, Konstadia Bakalianou, Ioannis D. Gkegkes</p>
					<p>Abstract: The change in life expectancy affects the clinical presentation and the prognosis of elderly patients with gynecological cancer. The in-crease of life expectancy and increased numbers of elderly patients, the healthcare systems have to deal more frequently with patients who are not simply older adults but have also severe comorbidities and physiological, psychological, functional, and social needs that require individualised management. Discussing every individual after detailed assessment in a multidisciplinary meeting is extremely important. Several studies have shown that elderly patients with gynecological malignancies are not treated to the same extent as young-er patients and have lower odds of receiving standard care according to the oncological protocols. Individualization of management in these patients could be identified in several studies in the literature showing that increasing age at diagnosis predicts deviation from guidelines for surgical therapy, adjuvant radiotherapy or chemotherapy. The authors performed a literature review to clarify whether there are any changes in the treatment of such patients, and whether their management should be considered to be individualized, depending on their age and comorbidities.</p>
					<p><a href="https://foliamedica.bg/article/47920/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/47920/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Invited Review</category>
		    <pubDate>Wed, 30 Sep 2020 17:40:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Large-cell Neuroendocrine Carcinoma of the Endometrium in Myomatous Uterus</title>
		    <link>https://foliamedica.bg/article/49815/</link>
		    <description><![CDATA[
					<p>Folia Medica 62(2): 412-417</p>
					<p>DOI: 10.3897/folmed.62.e49815</p>
					<p>Authors: Spasimir T. Shopov, Benyamin L. Anavi, Dobrin K. Krastev</p>
					<p>Abstract: Large-cell neuroendocrine carcinoma of the endometrium is an insufficiently researched aggressive tumor with a short survival regard&shy;less of the treatment type.We present here the 38th consecutive case of literature reported cases of large cell neuroendocrine carcinoma of the endometrium (posi&shy;tive for synaptophysin, CD56, chromogranin A, p53, and Vimentin) found in the myomatous uterus of a 76-year-old woman.We also describe in the study the morphological algorithm for differentiation of malignant blastomas with small (under 10 %) neuro-endocrinal component.Accumulated clinical and morphological evidence raises the question whether the large-cell and the small-cell neuroendocrine carcino&shy;mas are just different variations according to their histology and topical occurrence (uterine body/cervix) or they are just independent forms with their respective clinical signs, morphology, treatment, and prognosis.</p>
					<p><a href="https://foliamedica.bg/article/49815/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/49815/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Case Report</category>
		    <pubDate>Tue, 30 Jun 2020 19:28:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>The Role of miRNAs and lncRNAs in Laryngeal Squamous Cell Carcinoma - a Mini-Review</title>
		    <link>https://foliamedica.bg/article/49842/</link>
		    <description><![CDATA[
					<p>Folia Medica 62(2): 244-252</p>
					<p>DOI: 10.3897/folmed.62.e49842</p>
					<p>Authors: Silva G. Kyurkchiyan, Todor M. Popov, Vanyo I. Mitev, Radka P. Kaneva</p>
					<p>Abstract: Laryngeal squamous cell carcinoma is a common malignancy in men. Bulgaria is one of the countries in Europe with the highest incidence and mortality rates of the aggressive, severe disease of laryngeal cancer. Proven etiological factors are the abuse of tobacco and alcohol beverages. Despite the progress of technologies of multimodal medical treatment, survival rates have not reached satisfactory levels. Over the last few decades, scientific and clinical research data have led to a growing interest in exploring potential biomarkers. In the last years, non-coding RNAs have become promising biomarkers. They are important key regulators in both normal and tumour specific biological processes as well as in the response to environmental factors and treatment, including chemo- and radiotherapy. Studies have shown ectopic expression of a number of ncRNAs in laryngeal cancer. Published data provide evidence of the lncRNAs and miRNAs that could help us better understand complex carcinogenesis in laryngeal cancer and would provide reliable diagnostic, prognostic and predictive biomarkers.</p>
					<p><a href="https://foliamedica.bg/article/49842/">HTML</a></p>
					
					<p><a href="https://foliamedica.bg/article/49842/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Invited Review</category>
		    <pubDate>Tue, 30 Jun 2020 19:28:00 +0000</pubDate>
		</item>
	
	</channel>
</rss>
	